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Pathogenesis and Prevention of
Vascular Access Failure
Rebecca Hudson, David Johnson and Andrea Viecelli
Abstract
Dialysis vascular access failure is common, is rated as a critical priority by both
patients and health professionals, and is associated with excess morbidity, mortality
and healthcare costs. This chapter will discuss the mechanisms underpinning vas-
cular access failure as well as strategies for preventing this adverse outcome,
including systemic medical therapies (such as antiplatelet agents, fish oils, statins,
inhibitors of the renin-angiotensin-aldosterone system, and calcium channel
blockers), and local therapeutic interventions including innovative surgical tech-
niques, minimally invasive AVF creation, far infra-red therapy, perivascular appli-
cation of recombinant elastase, endothelial loaded gel foam wrap (Vascugel), and
antiproliferative agents such as sirolimus (Coll-R) and paclitaxel-coated balloon
angioplasty.
Keywords: arteriovenous fistula, arteriovenous graft, arteriovenous shunt, aspirin,
cardiovascular agents/therapeutic use, clinical research, endovascular procedures,
end-stage kidney disease, fish oils, graft occlusion, hemodialysis, maturation, risk
factors, statins, thrombosis, treatment outcome, vascular access, vascular patency
1. Introduction
The prevalence of end-stage kidney disease (ESKD) is increasing in the presence
of a growing diabetic and aging population [1, 2]. Hemodialysis remains the most
common form of kidney replacement therapy [3–5], with over 2 million people on
hemodialysis worldwide [6]. To maintain successful hemodialysis, functional vas-
cular access is required [7]. Hemodialysis vascular access consists of three forms: the
arteriovenous fistula (AVF), the arteriovenous graft (AVG), and the central venous
catheter (CVC). The AVF is a connection between a native artery and vein that is
created via an end-to-side vein-to-artery anastomosis [8]. AVGs are created by
interposing a prosthetic graft (classically with polytetrafluorethylene [PTFE])
between an artery and a vein [8]. The key requirements of such access are sufficient
blood flow rate, low flow resistance, a low rate of complications and, for AVF and
AVG, ease of cannulation.
A mature native AVF is considered superior to a synthetic AVG or CVC due to
better long-term outcomes, including reduced rates of thrombosis, infection and
interventions to maintain patency [9–11]. Balanced against these benefits, as a result
of early thrombosis, neointimal hyperplasia formation and inadequate vasodilation
(outward remodeling), between 20 and 60% of AVFs fail to mature to an adequate
caliber to allow repeat cannulation and provide sufficient blood flow for
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hemodialysis and thereby prevent timely usability of the AVF for hemodialysis [9].
AVGs can be used within days of access creation but long-term, they are at higher
risk of developing venous stenosis, thrombosis and infection compared to a func-
tioning AVF [12]. More than 50% of AVGs thrombose within 12 months of creation
and they require significantly more interventions to maintain patency compared to
a functioning AVF [12–14]. CVCs can be used immediately after insertion, but their
long-term use is discouraged in light of the significantly higher risks of thrombosis,
catheter-associated bacteremia and inadequate solute clearance [15–17].
Vascular access dysfunction is a major cause of morbidity, mortality and excess
healthcare costs [9, 18–20]. Indeed, healthcare professionals, patients and care-
givers consider vascular access function a top priority of research in hemodialysis
and clinical practice [21]. There have been recent advances in the understanding of
the biology of vascular access and its dysfunction, with neointimal hyperplasia
leading to venous stenosis and inadequate outward remodeling being identified as
the two major causes of dialysis vascular access dysfunction [7, 22]. This knowledge
has led to the identification of potential therapeutic targets and the development of
novel interventions to improve and maintain vascular patency [17].
This chapter will discuss the risk factors for, and pathogenesis of arteriovenous
access failure. The advances in the understanding of arteriovenous access failure
have led to the development of therapeutic targets and novel therapeutic interven-
tions including systemic medical therapies with pleiotropic effects (such as
antiplatelet agents, fish oils, statins, inhibitors of the renin-angiotensin-aldosterone
system [RAAS], and calcium channel blockers), and local therapeutic interventions
including innovative surgical techniques, minimally invasive AVF creation, far
infra-red therapy, perivascular application of recombinant elastase, endothelial
loaded gel foam wrap (Vascugel), and antiproliferative agents such as sirolimus
(Coll-R) and paclitaxel-coated balloon angioplasty.
2. Clinical predictors of arteriovenous access failure
Key contributors to successful AVF maturation and long-term function include
adequate inflow properties determined by the size and quality of the feeding artery,
cardiac output and blood pressure; anastomotic properties concerning the patent
anastomosis between the artery and vein/interposition graft; and adequate outflow
properties, which in turn are determined by the size and quality of the vein and
presence or absence of collateral or accessory veins. The significance of these three
factors in determining vascular access success highlight the importance of vascular
mapping and planning prior to fistula creation.
Inflow properties are influenced by the location of the AVF, with patency
increasing as the size of the feeding artery is increased (distal to proximal) [23].
Despite this, the distal radio cephalic AVF on the non-dominant side of the patient
is the preferred initial site of AVF for vascular access [23], partly due to patient
comfort along with the preservation of additional vascular access sites for future
use. Female gender has been identified as a risk factor for failure of fistula matura-
tion and survival, with investigations discovering significantly poorer outcomes of
AVFs in females in comparison to males, though the reasons underpinning this are
unclear [24–27]. It has been proposed that females have smaller vessels with asso-
ciated decreased luminal diameters in comparison to males; however, this has not
been consistently found to be a factor in unsuccessful AVFs [28, 29].
Key determinants of both inflow properties and anastomosis patency are the
comorbidities of the patient undergoing AVF creation, influencing outcome via
unfavorable effects on hemodynamics, with the most adverse effects seen from
2
Vascular Access Surgery - Tips and Tricks
peripheral arterial disease, cardiovascular disease and diabetes mellitus. Peripheral
arterial disease interferes with the remodeling process required to achieve a func-
tioning fistula, involving the development of neointimal hyperplasia and calcifica-
tion, causing increased arterial stiffness and decreased elasticity [30]. Woods et al.
[31] conducted a study involving 784 incident hemodialysis patients and found a
24% increased risk of AVF failure in those with peripheral arterial disease. This
failure is attributable to the fact that for vascular access to be a success, it is essential
that the artery used in the creation of the fistula is able to adequately increase
diameter allowing for the increased blood flow required to supply the fistula and
distal tissues [32, 33].
In relation to cardiac disease, its adverse impact on fistula maturation is due to
poor cardiac output and associated poor blood flow to the fistula, resulting in worse
outcomes [34].
Diabetes mellitus is associated with increased risks of intimal hyperplasia [35],
and peripheral arterial disease [36], with these risks exaggerated further in the
chronic kidney disease population leading to an appreciable rate of AVF failure in
this group [27, 37, 38].
Advancing age has been cited as a risk factor for failure of AVF maturation and
survival, although this proves difficult to quantify with age also being a surrogate
marker for increasing burden of comorbidities. Studies have indicated an increased
failure rate of AVFs in ‘older patients’ with the definition of those greater than or
equal to 65 years of age [39–41], contrasting with other literature which were
unable to identify significant differences in functional access outcomes for older
patients [26, 42].
Race and ethnicity have also been identified as risk factors for failure of AVF
maturation, though again this has not been consistently replicated in the literature
[43]. Studies however have identified AVF failure rate being more common in those
of African racial background in comparison to Caucasians; along with Hispanics
when compared with non-Hispanics [40, 41, 44].
A pertinent factor affecting the anastomosis and therefore the outcomes of AVFs
includes both the experience of the surgeon in creating the fistula, as well as the
technical issues associated with utilizing and managing the fistula. The formation of
AVFs is difficult, with numerous studies indicating that there is a higher incidence
of successful AVFs if the surgery is performed by an experienced vascular surgeon
[45–49], with the emphasis being placed on the number of AVFs created over the
total years of training [48, 50].
Outflow dynamics are influenced by several factors, one of which is obesity.
Obesity is described as a risk factor for failure of vascular access separate to the
increased incidence of diabetes in this group. It was observed that obese patients
experienced poor secondary patency in a study by Kats et al. [51], with the under-
lying theory that this was due to the increased soft tissue mass leading to venous
compression and outflow tract obstruction [52]. Diabetes has also been shown to be
a negative predictor of venous remodeling [53], directly impacting the outflow from
an AVF.
Following arteriovenous access creation, ongoing access surveillance, care and
cannulation by well trained staff/patient are paramount for preventing access fail-
ure [54–59].
3. Pathophysiology of arteriovenous access dysfunction
The pathogenesis of vascular access failure is complex with the common final
pathway being the combination of insufficient vessel vasodilation, negative
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(inward) vascular remodeling and neointimal hyperplasia resulting in luminal
narrowing and often associated thrombosis formation. The Achilles heel of this
process is the graft-vein anastomosis in AVG and the perianastomotic region in
AVF, respectively [1, 13]. The pathophysiologic cascade of events that lead to AVF
and AVG failure [16, 17] have been categorized into upstream events, characterized
by factors that lead to injury of endothelial—and smooth muscle cells and down-
stream events describing the cellular and cytokine responses that leads to
neointimal hyperplasia and inward remodeling [16] (Figure 1).
There are multiple factors that contribute to the upstream events of vascular
access dysfunction: (1) the proinflammatory uremic milieu that promotes endothe-
lial dysfunction [16, 60], (2) hemodynamic stressors at the anastomosis site due to a
combination of small and non-compliant vessels, low shear stress and turbulence
[16, 61, 62], (3) vascular injury at the time of fistula or graft formation due to vessel
manipulation through surgical technique or angioplasty [16, 61, 62], (4) a localized
inflammatory response involving cytokine release and macrophage migration
caused by the synthetic graft material used in the formation of the AVG [16], (5)
possible genetic predisposition to neointimal hyperplasia and vasoconstriction
[11, 16] (6) and repeat cannulation injury [16, 54].
After formation of an AVF, rapid increase in blood flow through the feeding
artery and draining vein causes vascular distension [63] leading to nitric oxide (NO)
synthesis by endothelial cells which results in vascular smooth muscle relaxation
and vasodilatation [64]. This response leads to structured vascular remodeling with
the driving forces of wall shear stress and tension [63] leading to an increase in
arterial and venous lumen size [65] and moderate thickening of the venous wall
assisting in maturation [66] and positive (outward) remodeling, which overall
results in a larger lumen and greater vascular success (Figure 2). In comparison, the
smooth muscle and endothelial injury sustained from the upstream events described
previously, trigger a cascade of downstream responses mediated through
proinflammatory leukotrienes, chemokines, cytokines, vasoactive molecules,
metalloproteinase and adhesion molecules that promote neointimal hyperplasia
Figure 1.
Pathogenesis of vascular access failure. This figure illustrates the different pathogenic mechanisms that result in
vascular access failure. Image re-used from Viecelli et al. [13] with permission from Wiley.
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formation and negative (inward) remodeling. In comparison to outward
remodeling, inward remodeling results in small lumen diameter and an increased
risk of access failure [17]. As such, neointimal hyperplasia if combined with com-
pensatory outward remodeling may not result in flow limiting stenosis due to
preservation of the luminal caliber, whereas neointimal hyperplasia combined with
impaired outward remodeling can result in hemodynamically significant vascular
stenosis and resultant thrombosis [17, 63].
4. Therapeutic interventions to prevent VA dysfunction
The following section will discuss systemic medical and local interventions
developed to minimize luminal narrowing caused by neointimal hyperplasia and
negative (inward) vascular remodeling.
4.1 Systemic medical therapies
4.1.1 Antiplatelet agents
Antiplatelet agents including aspirin, dipyridamole, clopidogrel and ticlopidine
are thought to prevent arteriovenous access failure primarily through their
antithrombotic effect. Clinical trial results will be discussed separately for each
agent given the differences in action of individual agents upon platelet aggregation,
function and vascular biology including anti-inflammatory and antiproliferative
properties.
4.1.1.1 Aspirin
Aspirin irreversibly inhibits platelet cyclooxygenase-1 and -2 enzymes via acet-
ylation, resulting in decreased formation of prostaglandin precursors and prosta-
glandin derivative thromboxane A2 [13]. Randomized controlled trials (RCT) on
the efficacy of aspirin in preventing arteriovenous access failure have shown incon-
sistent results, with two small studies favoring aspirin [67, 68] and two studies
showing no significant treatment benefit for the prevention of arteriovenous access
thrombosis and failure (Table 1) [5, 69]. In a small RCT of 44 patients, AVG
thrombosis was significantly reduced with 160 mg of aspirin daily compared to
Figure 2.
Vascular remodeling response post fistula creation: comparison of the effects of neointimal hyperplasia with
outward and inward vascular remodeling.
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Aspirin
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
duration
(months)
Primary outcome
(aspirin vs placebo)
Secondary outcome
(aspirin vs placebo)
Irish et al.
[5].
RCT 388 HTN (94%),
smoking history
(54%), DM (49%),
CAD (11%), PVD
(4%), CHD (4%),
CVD (3%)
AVF Aspirin 100 mg daily Placebo 3 Proportion of subjects
with AVF failure
(thrombosis,
abandonment or
cannulation failure) at
12 months
45% vs 47%, RR 1.05,
95% CI 0.84–1.31,
p = 0.68
AVF thrombosis at
12 months
20% vs 18%, RR 1.09,
95% CI 0.72–1.64,
p = 0.70
AVF abandonment at
12 months
24% vs 18%, RR 1.31,
95% CI 0.89–1.95.
p = 0.17
Cannulation failure at
12 months
40% vs 39%, RR 0.99,
95% CI 0.76–1.27,
p = 0.92
Harter et al.
[67]
RCT 44 NR AVG Aspirin 160 mg daily Placebo 4 Thrombosis at study end
(mean 5 months)
32% vs 72%, OR o.18,
95% CI 0.05–0.66,
p < 0.01
Number of thrombotic
events per patient
month
0.16 vs 0.46, p < 0.05
Andrassy
et al. [68]
RCT 92 NR AVF Aspirin 1000 mg
alternate days
Placebo 1 Thrombosis at 28 days
4% vs 23%, p < 0.05
NR
Dipyridamole and/or aspirin
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
duration
(months)
Primary outcome
(antiplatelet agent(s)
vs placebo)
Secondary outcome
(antiplatelet agent(s)
vs placebo)
Sreedhara
et al. [69]
RCT 107
(84 type I [new
AVG] and 23
NR AVG Aspirin 325 mg daily, or
Dipyridamole
225 mg + Aspirin
Placebo 18 Thrombosis at
18 months
Aspirin—type I 50% vs
RR of thrombosis with
new AVG
Aspirin 1.99, 95% CI
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type II
[thrombosed
AVG requiring
new AVG])
325 mg daily or
Dipyridamole 225 mg
daily
32%, type II 50% vs 80%
Aspirin + Dipyridamole
—type I 23% vs 32%,
type II 100% vs 80%
Dipyridamole—type I
17% vs 32%, type II 83%
vs 80%
0.88–4.48, p = 0.18
Dipyridamole 0.35,
95% CI 0.15–0.80,
p = 0.02
Clopidogrel
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
duration
(months)
Primary outcome
(clopidogrel vs
placebo)
Secondary outcome
(clopidogrel vs
placebo)
Ghorbani
et al. [73]
RCT 93 DM (26.9%) AVF Clopidogrel 75 mg daily Placebo 1.5 Primary AVF failure at
8 weeks
5.2% vs 21.6%; HR 0.72,
95% CI 0.41–1.01,
p = 0.03
Successful HD within
6 months of AVF
creation
92% vs 71%, p = 0.008
Dember
et al. [15]
RCT 877 Smoking history
(62%), DM (48%),
CAD (28%), CVD
(6%), PVD (3%)
AVF Clopidogrel 300 mg
loading dose followed
by 75 mg daily
Placebo 1.5 Thrombosis at 6 weeks
post fistula creation
12% vs 20%, RR 0.63,
95% CI 0.46–0.97,
p = 0.018
Failure to attain
suitability for dialysis
62% vs 60%, RR 1.05,
95% CI 0.94–1.17,
p = 0.40
Clopidogrel and aspirin
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
duration
(months)
Primary outcome
(antiplatelet agents vs
placebo)
Secondary outcome
(antiplatelet agents vs
placebo)
Kaufman
et al. [74]
RCT 200 DM (47%) AVG Aspirin 325 mg daily +
Clopidogrel 75 mg daily
Placebo NR Cumulative incidence of
thrombosis
HR 0.81, 95% CI 0.47–
1.40, p = 0.45
Cumulative incidence
of first graft
thrombosis for patients
with grafts without
previous thrombosis
(n = 111)
HR 0.52, 95% CI 0.22–
1.26, p = 0.14
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Ticlopidine
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
duration
(months)
Primary outcome
(ticlopidine vs
placebo)
Secondary outcome
(ticlopidine vs
placebo)
Grontoft
et al. [77]
RCT 250 DM (27%) AVF Ticlopidine 250 mg
twice daily
Placebo 1 Thrombosis at 4 weeks
12% vs 19%, OR 0.6, 95%
CI 0.30–1.18, p = 0.1
NR
Grontoft
et al. [75]
RCT 36 DM (61%) AVF Ticlopidine 250 mg
twice daily
Placebo 1 Thrombosis at 4 weeks
11% vs 47%, p < 0.05
NR
Fickerstrand
et al. [76]
RCT 18 NR AVF Ticlopidine 250 mg
twice daily
Placebo 1 Thrombosis at 4 weeks
25% vs 50%
NR
Omega-3 fatty acid supplementation (fish oil)
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
duration
(months)
Primary outcome (fish
oil vs placebo)
Secondary outcome
(fish oil vs placebo)
Irish et al.
[5]
RCT 536 HTN (94%),
smoking history
(54%), DM (49%),
CAD (11%), PVD
(4%), CHD (4%),
CVD (3%)
AVF 4 g of fish oil daily Placebo 3 AVF failure
(thrombosis,
abandonment or
cannulation failure) at
12 months
47% both groups, RR 1.03,
95% CI 0.86–1.23,
p = 0.78
AVF thrombosis at
12 months
22% vs 23%, RR 0.98,
95% CI 0.72–1.34,
p = 0.9
AVF abandonment at
12 months
19% vs 22%, RR 0.87,
95% CI 0.62–1.2,
p = 0.43
Cannulation failure at
12 months
40% vs 39%, RR 1.03,
95% CI 0.83–1.26,
p = 0.81
Lok et al.
[89]
RCT 196 HTN (86%), smoking
history (55%), DM
AVG 4 g of fish oil daily Placebo 12 Proportion of
participants
Rate of loss of graft
patency
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(53%), CAD (33%),
CHD (20%), PVD
(15%), CVD (14%)
experiencing graft
patency loss (thrombosis
or radiological or
surgical interventions) at
12 months
48% vs 62%, RR 0.78,
95% CI 0.60–1.03,
p = 0.06
IRR 0.58, 95% CI 0.44–
0.75
Radiological or surgical
intervention to
maintain patency
IRR 0.59, 95% CI 0.44–
0.78
Thrombotic events
IRR 0.5, 95% CI 0.35–
0.72
Bowden
et al. [90]
RCT 29 DM (69%), smoking
history (3%)
AVG 6 g of fish oil daily Placebo 8 Primary patency loss
(thrombosis or venous
outflow stenosis >50%
requiring angioplasty)
254  52 days, SEM 51.8
vs 254  35 days, SEM
34.6, NS
NR
Schmitz
et al. [88]
RCT 24 DM (58%) AVG 4 g of fish oil daily Placebo 12 Primary patency
(thrombosis free) at
12 months
75.6% vs 14.9%, p = 0.03
NR
Statin therapy
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(years)
Primary outcome
(statin vs placebo)
Secondary outcome
(statin vs placebo)
Herrington
et al. [94]
Post hoc
analysis of
RCT
2353 DM (22%), smoking
history (15%)
AVF (94%), AVG
(6%)
Simvastatin (20 mg)
plus Ezetimibe (10 mg)
daily
Placebo 5 Vascular access occlusive
event (access requiring
any revision procedure,
access thrombosis,
removal of an old
dialysis access, or
formation of new
permanent dialysis
access)
Access revision
18.6% vs 21.4%
RR 0.85, CI 0.67–1.08
Access thrombosis
9.3% vs 10.3%
RR 0.90, CI 0.64–1.27
Removal of old or
formation of new
vascular access
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29.7 vs 33.5%
RR 0.87, 95% CI 0.75–
1.00, p = 0.05
15% vs 16.2%
RR 0.93, CI 0.75–1.00
Herrington
et al. [94]
Post-hoc
analysis of
RCT
2439 DM (27%), smoking
history (14%)
AVF (89%), AVG
(11%)
Rosuvastatin 10 mg
daily
Placebo 4.5 Vascular access occlusive
event
28.9% vs 27.6%
RR 1.06, 95% CI 0.91–
1.23, p = 0.44
NR
Birch et al.
[91]
Retrospective
analysis
265 HTN (93%), DM
(53%)
AVF Statin therapy of
variable doses
(Simvastatin,
Atorvastatin,
Pravastatin,
Lovastatin)
No
statin
therapy
1.8 Interval of time to
angioplasty to maintain
AVF function
Mean time 8.9 vs
7.3 months, p = 0.25
Number of stenotic
lesions
98 vs 99 stenoses, p = 0.28
Primary AVF patency
(time from creation to
first intervention)
HR 1.17, 95% CI 0.747–
1.834, p = 0.49
Pisoni et al.
[97]
Retrospective
observational
cohort
analysis
601 HTN (92%), DM
(52%), CAD (29%),
PVD (18%), CVD
(10%)
AVF (53%), AVG
(47%)
Statin therapy not
specified
No
statin
therapy
6 Primary access failure
(access never useable for
dialysis) AVF 37% vs
38%, OR 0.97, 95% CI
0.59–1.58, p = 0.9
AVG 20% vs 14%, OR
1.52, 95% CI 0.76–3.09,
p = 0.23 Cumulative
access survival
AVF HR 1.26, 95% CI
0.76–2.16, p = 0.35
AVG HR 0.88, 95% CI
0.59–1.32, p = 0.54
NR
Righetti et al.
[34]
Case-control
study
60 HTN, dyslipidemia AVF Atorvastatin 10–20 mg
or Simvastatin 10–
20 mg daily and/or folic
acid 5 mg daily
No
statin or
folic
acid
therapy
3 Primary access patency
71.5% vs 39.1% after
2 years, p < 0.05
NR
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Saran et al.
[96]
Retrospective
observational
cohort
analysis
2462 HTN (87.8%), DM
(49.7%), Obesity
(35.9%)
AVF 900 (8.3%
on statin), AVG
1944 (9.6% on
statin)
Statin therapy of
varying doses
(Simvastatin,
Atorvastatin,
Pravastatin,
Lovastatin)
Fluvastatin)
NR 4 Primary access patency
(unassisted access
patency)
AVG RR 0.97, p = 0.805
AVF RR 0.93, p = 0.762
Secondary access
patency (assisted access
survival)
AVG RR 1.01, p = 0.920
AVF RR 1.03, p = 0.903
NR
Renin-angiotensin-aldosterone system blockers (angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers) therapy
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(years)
Primary outcome
(ACEI/ARB vs
placebo)
Secondary outcome
Chen et al.
[108]
Retrospective
analysis
42,244 HTN (81%), DM
(51%), CAD (24%),
Dyslipidemia (17%),
CVD (6%), PVD
(3%)
AVF 89.4%
(32.3% on an
ACEI, 15% on an
ARB)
AVG 10.6%
(6.2% on an
ACEI, 7.1% on an
ARB)
ACEI/ARB therapy of
varying doses
ACEI (Benazepril,
Enalapril, Lisinopril,
Quinapril, Captopril,
Fosinopril, Ramipril,
Cilazapril)
ARB (Candesartan,
Losartan, Irbesartan,
Valsartan, Olmesartan)
Non-
use
8 Primary patency loss
AVF
ACEI-HR 0.59, 95% CI
0.56–0.62, p < 0.05
ARB-HR 0.53, 95% CI
0.51–0.56, p < 0.05
AVG
ACEI-HR 0.56, 95% CI
0.48–0.64, p < 0.05
ARB-HR 0.54, 95% CI
0.47–0.61, p < 0.05
NR
Jackson et al.
[99]
Retrospective
cohort
analysis
332 DM (75%), HTN
(62%), smoking
history (36%)
AVF (64%) AVG
(36%)
ARB therapy of varying
doses (Irbesartan,
Losartan, Valsartan)
Non-
use
4 Primary patency loss
AVF
HR 0.35, 95% CI 0.16–
0.76, p = 0.008
AVG
HR 0.41, 95% CI 0.18–
0.95, p = 0.04
NR
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Saran et al.
[96]
Retrospective
analysis
2462 HTN (87.8%), DM
(49.7%), Obesity
(35.9%)
AVF 900 (18.7%
on ACEI, 4.1% on
ARB), AVG 1944
(17% on ACEI,
3.8% on ARB)
ACEI/ARB therapy of
varying doses
ACEI (Benazepril,
Enalapril, Lisinopril,
Quinapril, Captopril,
Fosinopril, Moexipril,
Ramipril)
ARB (Candesartan,
Losartan, Irbesartan,
Valsartan)
Non-
use
4 AVF
Unassisted primary
access patency
ACEI-RR 0.77, p = 0.09
ARB-RR 1.45, p = 0.06
Secondary access
patency
ACEI-RR 0.56, p = 0.01
ARB-RR 1.33, p = 0.31
AVG
Primary access patency
ACEI-RR 1.02, p = 0.85
ARB-RR 1.09, p = 0.63
Secondary access
patency
ACEI-RR 1.16, p = 0.13
ARB-RR 1.3, p = 0.17
NR
Sajgure et al.
[98]
Multicentre
observational
study
266 HTN (95%), DM
(57%)
AVF (33%) AVG
(67%)
ACEI of varying doses Placebo 2 Primary patency
duration (mean  SEM)
in days
AVG
672  68 vs 460  48,
HR 0.48, 95% CI 0.31–
0.73, p = 0.01
AVF
530  80 vs 501  76,
p = 0.45
NR
Calcium channel blocker therapy
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(months)
Primary outcome Secondary outcome
Saran et al.
[96]
Retrospective
observational
2462 HTN (87.8%), DM
(49.7%), Obesity
(35.9%)
AVF 900 (44.1%
on CCB), AVG
CCB therapy of varying
doses
(Amlodipine,
Non-
use
4 Unassisted primary
access patency AVG RR
0.86, p = 0.034
NR
12 Vascular
A
ccess
Surgery
-
T
ipsand
T
ricks
cohort
analysis
1944 (40.8% on
CCB)
Felodipine, Mibefradil,
Nifedipine, Verapamil,
Diltiazem, Isradipine,
Nicardipine,
Nisoldipine)
AVF RR 1.14, p = 0.3
Secondary access
patency
AVG RR 0.88, p = 0.153
AVF RR 1.16, p = 0.374
Chen et al.
[108]
Retrospective
analysis
42,244 HTN (81%), DM
(51%), CAD (24%),
Dyslipidemia (17%),
CVD (6%), PVD
(3%)
AVF 89.4%
(32.3% on CCB),
AVG 10.6%
(20.6% on CCB)
CCB therapy of varying
doses
(Amlodipine,
Felodipine, Nifedipine,
Verapamil, Diltiazem,
Isradipine,
Nicardipine)
Non-
use
8 Primary patency loss
AVF HR 0.485, CI
0.470–0.501
AVG HR 0.482, CI
0.442–0.526
NR
New surgical techniques to optimize flow dynamics
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(months)
Primary outcome Secondary outcome
Chemla et al.
[127]
Prospective
study
41 NR AVF Optiflow device NR 3 Unassisted maturation
(outflow vein >/= 5 mm
in diameter and flow >/=
500 ml/min not
requiring intervention to
maintain or promote
maturation)
72% at 42 days & 68% at
90 days
Unassisted patency
88% at 42 days & 78% at
90 days
NR
Bharat et al.
[126]
Comparative
study
125 HTN (43%), DM
(41%)
AVF pSLOT vs SLOT vs ETS NR 19 Formation of juxta-
anastomotic stenosis
pSLOT (3.7%, p = 0.04)
vs SLOT (8.3%, p = NS)
vs ETS (14%, p = NS)
Fistula failure
NR
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(pSLOT 16.7%, p = 0.01),
SLOT (33.3%, p = NS),
ETS (40.3%, p = NS)
Endovascular AVF creation
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(months)
Primary outcome Secondary outcome
Lok et al.
[114]
Prospective
study
80 HTN (92%), DM
(65%), CAD (22%),
CVD (15%), CHD
(12%), PVD (5%)
AVF Endovascular AVF
creation
NR 12 Percentage of
endovascular AVF
suitable for HD at
3 months
91%, 95% CI 81–97%
Primary patency at
12 months
69%, 95% CI 54–79%
Cumulative patency at
12 months
84%, 95% CI 71–91%
Far infrared therapy
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
duration
(months)
Primary outcome (FIT
vs placebo)
Secondary outcome
(FIT vs placebo)
Lin et al.
[115]
RCT 122 HTN (65%), DM
(40%)
AVF 40 min FIT, 3 times
weekly
Placebo 12 Rate of AVF malfunction
within 12 months
(thrombosis,
intervention required)
12% vs 29%, p = 0.02
Cumulative primary
unassisted AVF
patency
87% vs 70%, p = 0.01
Physiologic AVF
maturation
82% vs 60% p = 0.008
Lin et al.
[116]
RCT 145 HTN (54%), DM
(33%)
AVF 40 min FIT, 3 times
weekly
Placebo 12 Effect of FIT on access
flow at 12 months
13.2  114.7 vs 33.4 
132.3 ml/min, p < 0.021
AVF malfunction
12.9% vs 30.1%, p < 0.01
AVF unassisted patency
85.9% vs 67.6%, p < 0.01
NR
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Perivascular application of recombinant elastase
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(months)
Primary outcome
(PRT-201 vs placebo)
Secondary outcomes
(PRT-201 vs placebo)
Dwivedi
et al. [118]
RCT 89 DM (44%), HTN
(40%)
AVG Single dose escalation
of low (0.01, 0.03 mg),
medium (0.1, 0.3,
1.0 mg) and high (3.0,
6.0, 9.0 mg) PRT-201
immediately at AVG
placement
Placebo 12 Safety (adverse events)
13% vs 14%, NS
>/25% increase in
outflow vein diameter
intraoperatively
33% vs 15%, high,
p = 0.052
Percentage change in
intraoperative outflow
vein diameter
Low 13%, p = 0.01;
medium 15% p = 0.070;
high 12%, p < 0.001; vs
5% placebo
Percentage change in
intraoperative blood
flow volume
Low 19%, p = 0.34;
medium 36%, p = 0.09,
high 46%, p = 0.02; vs
15% placebo
Hye et al.
[117]
RCT 151 CAD (55%), DM
(45%), HTN (28%),
PVD (24%), CVD
(20%)
AVF PRT-201 at 0.01 mg or
0.03 mg applied once
to newly formed AVF
Placebo 12 Unassisted primary
patency at 12 months
10 mcg vs placebo; HR
0.69, 95% CI 0.39–1.22,
p = 0.19
30 mcg vs placebo; HR
0.67, 95% CI 0.38–1.19,
p = 0.17
Secondary patency at
12 months
10 mcg vs placebo; HR
0.79, 95% CI 0.33–1.92,
p = 0.61 30 mcg vs
placebo; HR 0.76, 95%
CI 0.31–1.89, p = 0.55
Unassisted maturation
at 3 months
10 mcg 67%, 30 mcg
70% vs placebo 54%, NS
Luminal stenosis
(hemodynamically
significant) at
3 months
10 mcg 41%, 30 mcg 35%
vs placebo 40%, NS
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Vascugel
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(months)
Primary outcome
(Vascugel vs placebo)
Secondary outcomes
(Vascugel vs placebo)
Conte et al.
[121]
Phase I/II
clinical study
57 CAD (100%), DM
(68%), Dyslipidemia
(51%)
AVF (47%) AVG
(53%)
Vascugel placement at
newly formed access
Placebo 6 Safety at 30 days
(incidence of infection,
intervention and
thrombosis)
10.9% vs 21.1%, NS
Primary patency
AVG 38% vs 23%, NS
AVF 60% vs 62%, NS
Assisted primary
patency
AVG 72% vs 58%, NS
AVF 96% vs 88%, NS
Antiproliferative agents—COLL-R (drug-eluted combination product of collagen membrane and sirolimus)
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(months)
Primary outcome Secondary outcomes
Paulson et al.
[122]
Phase II
clinical study
12 HTN (83%), DM
(8%)
AVG Surgical placement of
PTFE grafts and COLL-
R
NR 24 Safety (freedom from
device related adverse
events)
Endpoint met, nil adverse
events
Pharmacokinetics of
sirolimus release
Whole blood sirolimus
levels reached a mean
peak of 4.8 ng/mL at 6 h
and were less than 1 ng/
mL at 1 week
Success of COLL-R
implantation
100% success
Primary unassisted
graft patency
75% at 12 months and
38% at 24 months
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Paclitaxel-coated balloon angioplasty
Trial Study Number of
participants
Co-morbidities Access type Intervention Control Treatment
follow-up
(months)
Primary outcomes
(PCB vs HPB)
Secondary outcomes
(PCB vs HPB)
Kitrou et al.
[123]
RCT 40 NR AVF PCB treatment of
failing AVF
HPB 12 Device success
35% vs 100%, p < 0.001
Anatomic success
100% both groups
Clinical success
100% both groups
Target lesion
revascularization-free
survival
PCB 308 days; HPB
161 days; HR 0.478; 95%
CI 0.236–0.966, p = 0.03
Dialysis circuit primary
patency
PCB 270 days; HPB
161 days; HR 0.479; 95%
CI 0.237–0.968;
p = 0.04
Procedure related
complications
Nil
Katsanos
et al. [124]
RCT 40 DM (20%), HTN
(13%)
AVF (35%), AVG
(65%)
PCB treatment of
failing access
HPB 6 Primary patency of
treated lesion
70% vs 25% p < 0.001,
HR 0.30, 95% CI 0.12–
0.71, p = 0.006
Device success
45% vs 100%, p < 0.001
Procedural success
100% both groups
Dialysis circuit survival
95% vs 90%, p = 0.274;
HR 0.33, 95% CI 0.03 to
3.36, p = 0.349
RCT, randomized controlled trial; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; PVD, peripheral vascular disease; CHD, congestive heart disease; CVD, cerebrovascular disease; AVF,
arteriovenous fistula; AVG arteriovenous graft; mg, milligrams; RR, relative risk; CI, confidence interval; NR, not reported; OR, odds ratio; HR, hazard ratio; IRR, incident rate ratio; SEM, standard error of the
mean; NS, not significant; HD, hemodialysis; ACEI, angiotensin-converting enzyme inhibition; ARB, angiotensin II typ. 1 receptor blockers; pSLOT, piggybacking straight-line onlay technique; SLOT, side-to-side
straight-line onlay technique; ETS, end-to-side; FIT, far infrared therapy; PRT-201, perivascular application of recombinant elastase; PTFE, polytetrafluoroethylene; PCB, paclitaxel-coated balloon angioplasty;
HPB, high pressure balloon angioplasty.
Table 1.
Summary of trial results of systemic medical therapies and local interventions on vascular access outcomes in hemodialysis patients.
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placebo (32% vs 72%, odds ratio [OR] 0.18, 95% confidence interval [CI] 0.05–0.66,
p < 0.01) after a mean follow-up of 5 months [67]. In contrary, a randomized,
double-blind, placebo-controlled parallel group study [69] assessing the effect of
dipyridamole and/or aspirin on AVG thrombosis showed a non-significant increase
in thrombosis in 10 of 20 patients (50%) treated with 325 mg of aspirin daily
compared to 6 of 19 (32%) patients on placebo (relative risk [RR] 1.99, 95% CI
0.88–4.48, p = 0.18) over a 18-month follow-up period. Inconsistent outcomes have
also been described for aspirin used for prevention of AVF failure. In a study of 92
participants [68] randomized to 1000 mg of aspirin on alternate days over a 28 day
period or placebo, the frequency of AVF thrombosis was reduced more than 4-fold
by aspirin compared to placebo (2 of 45 [4.4%] vs 11 of 47 [23.4%], p < 0.05).
However, the most recent and largest RCT showed no significant reduction in AVF
failure at 12 months in 488 patients randomized to receive 100 mg of aspirin or
placebo for 3 months following AVF creation. AVF failure was defined as a com-
posite of AVF thrombosis, AVF abandonment and cannulation failure [5]. Neither
the composite binary outcome (45% participants treated with aspirin vs 43%
treated with placebo, RR 1.05, 95% CI 0.84–1.31, p = 0.68) nor the individual
outcome components were reduced by low-dose aspirin: AVF thrombosis (20% vs
18%, RR 1.09, 95% CI 0.72–1.64, p = 0.70), AVF abandonment (24% vs 18%, RR
1.31, 95% CI 0.89–1.95, p = 0.17) and cannulation failure (40% vs 39%, RR 0.99,
95% CI 0.76–1.27, p = 0.92) [5]. Differences in treatment dose, duration, sample size
and outcome definition makes comparison of treatment efficacy across trials diffi-
cult. Considering the cumulative evidence to date, there remains considerable
uncertainty as to whether aspirin reduces arteriovenous access failure.
4.1.1.2 Dipyridamole
Dipyridamole impairs platelet aggregation by inhibition of adenosine deaminase
and phosphodiesterase, causing an increase of adenosine, adenine nucleotides and
cyclic adenosine monophosphate (cAMP) levels [70]. As a phosphodiesterase inhibi-
tor, it reduces vascular smooth muscle proliferation, and may prevent neointimal
hyperplasia, stenosis and thrombosis of arteriovenous access [70, 71]. A randomized,
double-blind, placebo-controlled parallel group study [69] of 107 patients with ESKD
assessed the effect of dipyridamole (225 mg daily) and/or aspirin (325 mg daily) on
the rate of AVG thrombosis over a treatment duration of 18 months (Table 1). The
treatment groups were divided into two cohorts, type I which included patients with
new AVGs (84 patients) vs type II which included patients with previously placed
AVGs who had suffered graft thrombosis requiring thrombectomy or revision (23
patients). Dipyridamole reduced AVG thrombosis rates compared to placebo (RR
0.35, 95% CI 0.15–0.80, p = 0.02), used alone (17% vs 32%) or in combination with
aspirin (23% vs 32%). A multicenter RCT involving 649 patients with new AVGs
randomized individuals to dipyridamole (200 mg extended release twice daily) plus
aspirin (25 mg twice daily) or placebo over 4.5 years with an additional 6-month
follow-up [72]. At 12 months, the primary outcome of primary unassisted patency
loss (patency without thrombosis or requirement of an intervention) occurred in 28%
of patients treated with dipyridamole and aspirin compared to 23% receiving placebo
(hazard ratio [HR] 0.82; 95% CI 0.68–0.98, p = 0.03) [72]. Pertaining to the evidence
presented, dipyridamole alone or in combination with aspirin may be beneficial in
preventing primary AVG failure.
4.1.1.3 Clopidogrel
Clopidogrel and ticlopidine are classed as thienopyridines. The active metabolite
they produce irreversibly blocks the protein P2y12 component of the adenosine
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diphosphate (ADP) receptors on the platelet surface, preventing activation of the
GPIIb/IIa receptor complex and reducing platelet aggregation [13]. The effects of
clopidogrel (300 mg load followed by 75 mg daily) on access failure were evaluated
in an RCT involving 877 patients undergoing AVF formation (Table 1). The rate of
early fistula thrombosis (within 6 weeks) was lower with treatment (53 of 436
patients, 12.2%) compared to placebo (84 of the 430, 19.5%; RR 0.63, 95% CI 0.46–
0.97, p = 0.18) [15], however, this benefit did not translate into an increase in the
proportion of AVFs that became suitable for hemodialysis (61.8% vs 59.5%; RR
1.05, 95% CI 0.94–1.17, p = 0.4) [15]. A smaller RCT of 93 patients found that,
compared with placebo, clopidogrel resulted in a lower risk of early fistula throm-
bosis (5.2% vs 21.6%; HR 0.72, 95% CI 0.41–1.01, p = 0.03) and a higher rate of first
successful dialysis using the newly created AVF (92.3% vs 70.5%) [73]. In contrast,
no benefit was identified from clopidogrel 75 mg and aspirin 325 mg vs placebo on
graft thrombosis in an RCT involving 200 participants undergoing hemodialysis
with newly formed AVGs (HR 0.81, 95% CI 0.47–1.40, p = 0.45) [74]. Considering
the evidence to date, there remains uncertainty as to whether clopidogrel results in
a clinically meaningful benefit beyond prevention of early thrombosis.
4.1.1.4 Ticlopidine
Three RCTs investigated the effects of ticlopidine on AVF thrombosis at 4 weeks
(Table 1). Two small RCTs [75, 76] demonstrated that AVF thrombosis occurred in
fewer patients receiving ticlopidine as compared with placebo. Grontoft et al. [75]
studied 36 participants and showed that AVF thrombosis at 4 weeks was reduced in
participants treated with 250 mg ticlopidine twice daily (11%) compared to placebo
(47%, p < 0.05). In a pilot study of 18 participants [76], 250 mg ticlopidine given
twice daily over 1 month resulted in half the thrombosis rates compared to placebo
(25% vs 50% respectively). A multicenter RCT involving 250 participants [77]
showed that ticlopidine did not significantly reduce AVF thrombosis compared to
placebo at 4 weeks (12% vs 19%, OR 0.6, 95% CI 0.30–1.18, p = 0.1). A subsequent
systematic review and meta-analysis of these trials [78] favored the use of
ticlopidine in access thrombosis as a beneficial treatment (OR 0.45, 95% CI 0.25–
0.82, p = 0.009).
A meta-analysis of 21 RCTs using any type of antiplatelet drug to prevent
arteriovenous access failure demonstrated a 51% reduction in patency loss of AVFs
with antiplatelet therapy compared to placebo (6 trials, 1222 participants, RR 0.49,
95% CI 0.30–0.81), while clinical benefits in preventing AVG thrombosis remained
uncertain (3 trials, 956 participants, RR 0.94, 95% CI 0.80–1.10) [79].
Based on the available evidence, there may be a short-term benefit of
antiplatelet agents in reducing arteriovenous access thrombosis [15, 78–80], though
clinically meaningful benefits, including improved long-term patency or access
usability for dialysis, have not been found [15, 79]. Therapeutic approaches
targeting vascular remodeling and neointimal hyperplasia may be more beneficial in
the longer term [13].
4.1.2 Omega-3 fatty acid supplementation (fish oil)
Omega-3 fatty acids (the active component of fish oil) are thought to reduce
arteriovenous access thrombosis and improve maturation [81] through their
antiproliferative [82], antiaggregatory [83], anti-inflammatory [84], antioxidant
and vasodilatory effects [85–87].
Two RCTs have assessed the effect of fish oil on AVG patency (Table 1)
[88, 89]. The largest study involved 196 patients with newly created AVGs treated
with 4 g of fish oil or placebo for 12 months [89]. There was no statistically
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significant difference in the proportion of participants experiencing graft patency
loss (thrombosis or radiological or surgical interventions) at 12 months between fish
oil (48%) and placebo (62%, RR 0.78, 95% CI 0.60–1.03, p = 0.06). However,
participants treated with fish oil experienced lower rates of loss of graft patency
(incident rate ratio [IRR] 0.58, 95% CI 0.44–0.75), radiological or surgical inter-
ventions (IRR 0.59, 95% CI 0.44–0.78) and thrombotic events (IRR0.5, 95% CI
0.35–0.72). Another RCT including 24 patients randomized to treatment with fish
oil or placebo for 12 months found that fish oil treatment led to greater primary
patency (thrombosis free) after 12 months of follow-up (75.6% vs 14.9% respec-
tively, p = 0.03) [88]. An RCT by Bowden et al. [90] was unable to replicate these
findings in 29 participants, with no difference in the mean time to primary patency
loss (thrombosis or venous outflow stenosis >50% requiring angioplasty) in the
treatment group (254  52 days, standard error of the mean [SEM] 51.8) compared
to the placebo group (254  35 days, SEM 34.6) over the 8-month follow-up period.
The heterogeneity in outcome definitions (primary patency loss vs thrombosis)
makes comparison across trials difficult. Although a risk reduction in graft throm-
bosis was described in a meta-analysis of data from four trials, this analysis incor-
porated events other than graft thrombosis including infection [86] and
interventions [90]. When only including the trials that assessed the frequency of
graft thrombosis [78], fish oil was no longer associated with a significant treatment
benefit compared to placebo (OR 0.24; 95% CI, 0.03–1.95).
A large multicenter trial (Omega-3 fatty acids (fish oils) and aspirin in vascular
access outcomes in renal disease [FAVORED]) [5] is the only RCT to date to
examine the effect of fish oil on AVF failure. This trial included 567 patients with
newly created AVF randomized to 4 g of fish oil daily or matching placebo for 3
months post AVF creation. At 12-month follow-up, no significant differences
between the fish oil and placebo groups were identified for the primary composite
outcome of AVF failure (47% identified in both groups, RR 1.03, 95% CI 0.86–1.23,
p = 0.78) or for the individual components of the composite including AVF throm-
bosis (22% vs 23%, RR 0.98, 95% CI 0.72–1.34, p = 0.9), fistula abandonment (19%
vs 22%, RR 0.87, 95% CI 0.62–1.2, p = 0.43) or cannulation failure (40% vs 39%, RR
1.03, 95% CI 0.83–1.26, p = 0.81) [5].
A recent meta-analysis of all RCTs (5 trials, 833 participants) evaluated the
effect of fish oil supplementation in preventing arteriovenous access failure using
standardized outcome definitions [81]. Key findings included that fish oil supple-
mentation prevented primary patency loss with moderate certainty (RR 0.81, 95%
CI 0.68–0.98), and that low quality evidence suggested that fish oil may have little
effect on dialysis suitability failure (RR 0.95, 95% CI 0.73–1.23), access abandon-
ment (RR 0.78, 95% CI 0.59–1.03), need for interventions (RR 0.82, 95% CI 0.64–
1.04) or all-cause mortality (RR 0.99, 95% CI 0.51–1.92).
4.1.3 Statin therapy
Statins have been shown to reduce inflammation in the ESKD population, while
also improving endothelial function beyond the effect of cholesterol lowering [91].
There is experimental evidence that statins reduce neointimal hyperplasia and
vascular remodeling, which appears to be mediated by the reduction of vascular
endothelial growth factor-A and matrix metalloproteinase (MMP) [92], and pro-
motion of vasodilatation (via endothelial derived NO) [93].
An ancillary analysis of the Study of Heart and Renal Protection (SHARP) RCT
comparing the effects of simvastatin/ezetimibe 20 mg/10 mg vs placebo on vascular
access occlusive events (defined as any access revision procedure, access thrombo-
sis, removal of an old dialysis access, or formation of new permanent dialysis
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access) in 2353 participants (94% AVF, 6% AVG) (Table 1) [94]. Simvastatin plus
ezetimibe resulted in a 13% reduction in vascular occlusive events compared with
placebo (RR 0.87, 95% CI 0.75–1.00, p = 0.05). Results were broadly similar for the
individual components of the composite outcomes. However, the same group was
unable to replicate this result in a post hoc analysis of the AURORA (A Study to
Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assess-
ment of Survival and Cardiovascular Events) trial cohort [94]. Specifically, occlu-
sive vascular events were comparable between the rosuvastatin and placebo groups
(28.9% vs 27.6%, respectively, RR 1.06, 95% CI 0.91–1.23, p = 0.44). When the
SHARP and AURORA results were pooled, low density lipoprotein cholesterol
(LDL-C) lowering therapy did not significantly reduce vascular occlusive events.
These results were limited by the post hoc analysis of exploratory trial outcomes
and the failure to include other large studies of cholesterol-lowering therapy (such
as the Der Deutsche Diabetes Dialyze [4D] study [95]), such that results should be
considered hypothesis-generating only.
Retrospective observational cohort analyses by Saran et al. [96] and Pisoni et al.
[97] found statins were not beneficial in improving cumulative fistula survival.
Specifically, statin therapy did not improve access maturation [97] or primary
access patency [96]. Similarly, a retrospective review of 265 patients, of which 90%
were on either simvastatin or atorvastatin, found that statin therapy did not affect
the number of stenotic lesions in AVFs or time to primary angioplasty [91].
Whereas a case-control study of 60 dialysis patients receiving either folic acid and/
or statin discovered improved primary patency in 35 patients with AVFs [34].
In summary, the evidence for benefits of statin use in the prevention of vascular
access complications in hemodialysis patients is based on observational trial data
and post hoc analysis of RCTs. To date, no RCT has been developed to determine
the effect of statin therapy on primary patency rates in newly formed vascular
access. There is currently insufficient evidence to support the routine use of statin
therapy for preserving vascular access.
4.1.4 Renin-angiotensin-aldosterone system blockers (angiotensin-converting enzyme
inhibitors and angiotensin II type I receptor blockers)
The renin-angiotensin-aldosterone system (RAAS) is an important modulator of
the vascular smooth muscle cell proliferation that occurs in the intimal layer of the
vein in response to injury [98]. Additionally, angiotensin II produced locally at the
site of injury can induce growth factors that further promote vascular smooth
muscle proliferation and a prothrombotic environment [98]. Blocking these path-
ways in animal models with the use of angiotensin-converting enzyme inhibition
(ACEI) has been shown to prevent smooth muscle cell proliferation and migration
[99, 100], inhibit intimal hyperplasia and extracellular matrix deposition [100–
102], promote venous dilation [103] and prevent platelet activation [104, 105].
In the clinical setting, the effects of ACEI and/or angiotensin II type 1 receptor
blockers (ARB) on primary and secondary arteriovenous access outcomes has been
confined to retrospective observational cohort studies with conflicting findings
(Table 1) [98, 99, 106–108]. A multi-center observational study by Sajgure et al.
[98] compared the use of ACEI vs placebo on primary patency duration in AVGs
(179 participants) and AVFs (87 participants) over a 24 month period. A longer
primary patency duration was observed in the treatment AVG group compared
with placebo (HR 0.48, 95% CI 0.31–0.73, p = 0.01), though no benefit was
observed with the use of ACEI in AVFs (p = 0.45). Chen et al. [108] performed a
retrospective analysis of the efficacy of ACEI and/or ARB therapy on primary
patency loss of AVGs and AVFs in 42,244 patients over a 96-month period
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(37,771 with AVFs [32.3% on an ACEI, 15% on an ARB], 4473 with AVGs [6.2% on
an ACEI, 7.1% on an ARB]). ACEI use was associated with prolonged primary
patency in both AVFs (HR 0.59, 95% CI 0.56–0.62, p < 0.05) and AVGs (HR 0.56,
95% CI 0.48–0.64, p < 0.05). Similarly, ARB use was shown to be beneficial in
AVFs (HR 0.53, 95% CI 0.51–0.56, p < 0.05), and AVGs (HR0.54, 95% CI 0.47–
0.61, p < 0.05) [108]. Furthermore, Jackson et al. [99] reported that ARB use
prolonged 1- and 2-year primary patency in both, AVFs (55.2% at 1 year, 49.1% at
2 years; HR 0.35, 95% CI 0.16–0.76, p = 0.008) and AVGs (50.2% at 1 year, 29.7% at
2 years; HR0.41, 95% CI 0.18–0.95, p = 0.039). An international, prospective,
observational study by Saran et al. [96] elucidated a clinically significant relation-
ship between ACEI use and reduction in secondary AVF failure (RR 0.56, p = 0.01)
and a trend toward improving primary AVF patency failure, while there was no
significant treatment benefit in AVGs (primary RR 1.02, p = 0.846, secondary RR
1.16, p = 0.133). The same study found no significant benefit associated with the use
of ARB in preventing primary or secondary patency failure in AVFs or AVGs.
Available evidence is limited by substantial heterogeneity of treatment agents, dose,
outcome definitions and study populations and unadjusted confounding associated
with the observational study design. Randomized-controlled trials to confirm
potential benefits of RAAS inhibitors are required.
4.1.5 Calcium channel blockers
Based on animal and human studies, calcium channel blockers (CCB) may
inhibit neointimal hyperplasia [109, 110] and thereby reduce maturation failure
[111] and restenosis post angioplasty [112]. In a prospective, observational study of
2313 participants (of which 970 were on CCB) [96], CCB use was associated with
prolonged primary patency of AVGs (RR 0.86, p = 0.034), while no association
with CCB was found for secondary AVG patency (RR 0.88, p = 0.153) as well as
primary (RR 1.14, p = 0.3) and secondary AVF patency (RR 1.16, p = 0.374)
(Table 1). A retrospective study by Chen et al. [108] including 42,244 patients
(37,771 with AVFs [32.3% on a CCB], 4473 with AVGs [20.6% on a CCB]),
described a significant relationship between CCB use and prolonged primary
patency in both AVF (HR 0.485, CI 0.470–0.501) and AVG (HR 0.482, CI 0.442–
0.526) groups. While there has currently been minimal investigation into the use of
CCB in prevention of vascular access failure, further research may be warranted
given the wide use of this antihypertensive agent in the hemodialysis population.
4.2 Local interventions
Targeted interventions to reduce upstream injury include new surgical tech-
niques [113] and endovascular access creation [114], interventions to mitigate
downstream responses include far infra-red therapy [115, 116], perivascular appli-
cation of recombinant elastase [117, 118] and endothelial loaded gel foam wrap
(Vascugel) [119–121], whereas antiproliferative agents including sirolimus [122]
and paclitaxel [123, 124] have been developed to prevent neointimal hyperplasia
and promote outward remodeling and vasodilatation [1, 13].
4.2.1 New surgical techniques to alter wall shear stress
Turbulent low-flow with low shear stress at the anastomosis leads to endothelial
dysfunction, increased oxidative stress and an inflammatory and prothrombotic
state, promoting AVF/AVG inward remodeling and neointimal hyperplasia
[16, 125]. Optimization of flow dynamics through novel surgical techniques aimed
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at changing the anatomical configuration is a potential strategy to minimize this
injury [17]. Baharat et al. [126] compared the use of the piggybacking Straight-Line
Onlay Technique (pSLOT) to the traditional end-to-side (ETS) and side-to-side
Straight-Line Onlay Techniques (SLOT), in a study of 125 patients (Table 1). They
found a significant reduction in juxta-anastomotic stenosis using the novel pSLOT
(3.7%) compared to traditional methods of ETS (14%) and SLOT (8.3%) (p = 0.04).
This was accompanied by a significant reduction in overall fistula failure (pSLOT
16.7%, ETS 40.3%, SLOT 33.3%, p = 0.01) over the median 19-month follow-up.
The Optiflow Vascular Anastomotic device is a sutureless device that is able to
provide reproducible anastomosis at a controlled geometry of 60° between the
artery and vein, resulting in reduced surgical time, and optimized flow patterns and
shear stress [13, 113], with a likely capability of shielding the perianastomotic region
and preventing stenosis with its prosthetic material [13, 113]. This device is thought
to clinically improve both vascular access maturation and patency [13]. Manson
et al. [113] demonstrated safety and technical practicality in a human pilot study
involving 10 patients. Subsequently, a prospective study of 41 patients performed at
two centers by Chemla et al. [127] evaluated the maturation, patency, and safety of
AVF using the Optiflow device. Unassisted maturation (defined as an outflow vein
>/= 5 mm in diameter and flow >/= 500 ml/min not requiring intervention to
maintain or promote maturation) was achieved in 72% of AVFs at 42 days and 68%
at 90 days, unassisted patency in 88% of AVFs at 42 days and 78% at 90 days, and
no serious device-related adverse events were reported [127]. In summary, the
Optiflow device has shown promise in very small sample sizes and requires further
evaluation in an RCT that is powered to confirm these clinical benefits.
4.2.2 Endovascular AVF creation
The creation of an AVF with an endovascular approach using a radiofrequency
magnetic catheter-based system is suggested to cause less vessel trauma, resulting in
a reduced stimulus for the formation of neointimal hyperplasia [13, 128]. Clinically
this has the potential to translate into improved vascular access maturation and
patency [13]. A prospective, single-arm, multicenter study (Novel Endovascular
Access Trial [NEAT]) enrolled 80 patients (57% pre-dialysis and 43% on dialysis)
who underwent endovascular arteriovenous anastomosis creation (Table 1) [114].
The AVF was successfully created in 98% of participants (95% CI 91–100%). Phys-
iologically suitable AVF dialysis, defined as a brachial artery flow ≥500 mL/min and
vein diameter ≥ 4 mm within 3 months, was achieved in 87% of participants (95%
CI 75–94%) and 64% (95% CI 48–78%) were able to receive prescribed hemodialy-
sis through the AVF using two-needle cannulation. Primary patency at 12 months
was 69% (95% CI 54–79%) and cumulative patency 84% (95% CI 71–91%), and 24
secondary AVF interventions were required in 19 participants (0.46/patient-year).
Serious procedure-related adverse events (access-site management, hemostasis and
pseudoaneurysm) occurred in 8% of participants. These results suggest that
endovascular AVF creation may be a viable, minimally invasive alternative for
creating vascular access. However, long-term outcomes are currently lacking and
comparison to open surgical techniques in a randomized controlled fashion may be
difficult due to the unique location and type of vessels used for AVF.
4.2.3 Far infrared therapy
Infrared radiation is an invisible electromagnetic wave, with wavelengths rang-
ing from 5.6 to 1000 μm [17]. This energy is perceived as heat by the thermorecep-
tors in the surrounding skin [116]. Far infrared therapy (FIT) has been shown to
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inhibit vascular smooth muscle cell proliferation and platelet aggregation [116],
promote vasodilation [129], improve endothelial function [130] and reduce oxida-
tive stress [13]. These pleiotropic effects upon vascular biology may be beneficial in
improving maturation and vascular patency [13, 116]. An RCT by Lin et al. [116]
involving 145 hemodialysis patients evaluated the effect of FIT on access blood flow
and unassisted patency in native AVFs over a 12-month period (Table 1). Com-
pared to placebo, FIT resulted in increased blood flow (13.2  114.7 vs 33.4 
132.3 ml/min, p < 0.021) and unassisted patency (85.9% vs 67.6% respectively, p
< 0.01) [116]. Additionally, Lin et al. [115] conducted an RCT involving 122
patients with advanced CKD pre-dialysis who underwent AVF creation. FIT applied
for 40 min three times a week for 12 months, resulted in lower rates of AVF
malfunction (thrombosis or requirement of intervention) compared with placebo
(12% vs 29% respectively p = 0.02), higher maturation rates (82% vs 60%
p = 0.008), and higher rates of cumulative unassisted AVF patency (87% vs 70%
p = 0.01) at 12 months [115]. A subsequent meta-analysis of RCTs and quasi-RCTs
by Wan et al. [131] included 21 studies and 1899 patients of whom 960 were treated
with FIT. The result of this meta-analysis demonstrated that FIT improved primary
AVF patency (pooled risk ratio [PRR] 1.24; 95% CI 1.12–1.37, p < 0.001), improved
vascular access blood flow (mean difference [MD], 81.69 ml/min; 95% CI 46.17–
117.21, p < 0.001), superior vascular access diameter level compared to control
(MD 0.36 mm; 95% CI, 0.22–0.51, p < 0.001) and reduced AVF occlusion rates
(PRR 0.2; 95% CI 0.08–0.46, p < 0.001) [131]. The quality of evidence provided in
this meta-analysis is limited by small-scale studies of short duration (maximum
12 months). Given the convenience of FIT application during dialysis sessions and
its non-invasive nature, this treatment strategy warrants further study to confirm
the proposed benefits in improving vascular access maturation and patency.
4.2.4 Perivascular application of recombinant elastase
Elastin is a protein that provides blood vessels with their elasticity enabling
control of vessel diameter [132]. Recombinant human type-1 pancreatic elastase
(PRT-201) preferentially cleaves the peptide bonds abundant in elastin [133, 134].
Fragmentation of elastin leads to vasodilation and inhibits migration of adventitial
myofibroblasts into the intimal layer [13, 135]. The rationale behind the use of PRT-
201 is the theoretical assumption that application after AVF creation should destroy
the elastin in the arteries and veins thereby resulting in faster AVF dilatation and
maturation [1, 13]. Due to difficulties with inactivation of the enzyme following
systemic administration, PRT-201 needs to be applied locally during surgery to
provide targeted antiprotease effect [136]. Animal studies reported an increase in
vessel diameter, blood flow, and inhibition of intimal hyperplasia with use of PRT-
201 [137, 138]. An RCT [118] of 89 patients comparing low (0.01, 0.03 mg),
medium (0.1, 0.3, 1.0 mg) and high (3.0, 6.0, 9.0 mg) dose PRT-201 vs placebo
applied during AVG creation reported a larger percentage increase in outflow vein
diameter intraoperatively with PRT-201 (5% placebo vs 13% [p = 0.01], 15%
[p = 0.070], 12% [p < 0.001] in the low, medium and high dose groups, respec-
tively) (Table 1). In contrast, only high dose PRT-201 led to a significant increase in
blood flow compared to placebo (15% placebo vs 19% [p = 0.34], 36% [p = 0.09],
46% [p = 0.02], low, medium and high doses respectively) [118]. Conversely, a
double-blind, randomized, placebo-controlled trial of a single local application of
PRT-201 in 151 patients with advanced kidney disease undergoing AVF creation
found no significant difference in unassisted primary patency over 1 year with low
dose PRT compared to placebo (HR 0.69, 95% CI 0.39–1.22, p = 0.19 for 10 μg PRT-
201 and HR 0.67, 95% CI 0.38–1.19, p = 0.17 for 30 μg PRT-201) [117]. While there
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is a potential immediate effect of high dose PRT-201 on intraoperative vein outflow
diameter and blood flow, clinically meaningful long-term outcomes have not yet
been addressed in adequately powered RCTs.
4.2.5 Endothelial loaded gel foam wrap (Vascugel)
Vascugel is an endothelial-cell-loaded wrap comprising a gel foam with alloge-
neic aortic endothelial cells [1, 53, 121]. Vascugel mediates its effects through the
local delivery of “functional” endothelial cells at the anastomosis to promote out-
ward vascular remodeling and prevent neointimal hyperplasia [1]. Preclinical stud-
ies involving porcine models of AVF and AVG have reported that local application
of Vascugel resulted in a reduction in thrombus formation and vessel wall inflam-
mation, an increase in luminal diameter and outward remodeling accompanied by
reductions in MMP-2 expression, neovascularization and adventitial fibrosis
[119, 120]. A phase II trial by Conte et al. [121] suggested that the use of Vascugel
was a safe approach for local response to injury control at anastomotic sites,
although it did not significantly affect primary and assisted patency rates in treated
AVF and AVG compared with placebo (Table 1). A retrospective analysis of this
trial showed an improved primary patency when Vascugel was used in AVGs of
diabetic patients (p = 0.05), although the results of such a post hoc analysis should
be interpreted with caution [53]. In summary, Vascugel has been identified as a safe
intervention, though its clinical benefit on vascular access function has not been
consistently demonstrated in human trials. Adequately powered RCTs investigating
its clinical application are still needed.
4.2.6 Antiproliferative agents: COLL-R (drug-eluted combination product of collagen
membrane and sirolimus)
Sirolimus (rapamycin) is an antiproliferative agent with immunosuppressive,
anti-inflammatory and antiproliferative effects [139, 140], that has been shown to
reduce vascular smooth muscle cell proliferation [13] and neointimal hyperplasia in
vascular access [122]. When delivered locally, sirolimus reduces neointimal hyper-
plasia in coronary re-stenosis [1, 141–143]. COLL-R is a drug-eluted combination
product of sirolimus and a collagen membrane, which can be implanted around the
adventitial surface either at the arteriovenous anastomosis of the AVF or at the graft-
vein anastomosis of the AVG [1, 13, 122]. Sirolimus is then eluted from the COLL-R,
inhibiting neointimal proliferation at the anastomosis [122], translating clinically to a
potential improvement in vascular access maturation and patency [13]. A single-arm
phase II study by Paulson et al. [122] containing a cohort of 12 hemodialysis patients
undergoing AVG formation with intraoperative COLL-R placement demonstrated
primary unassisted patency rates of 75% at 12 months and 38% at 24 months and a
thrombosis rate of 0.37 episodes per patient year (Table 1) [122]. In a sub-group of 5
patients, whole blood sirolimus levels reached a mean peak of 4.8 ng/mL at 6 h and
were less than 1 ng/mL at 1 week. Results from a phase III RCT evaluating AVF
suitability for dialysis at 6 months with and without a perivascular Sirolimus-Eluting
Collagen Implant are currently awaited (NCT02513303).
4.2.7 Paclitaxel-coated balloon angioplasty
Drug-eluting balloons can deliver antiproliferative agents (such as paclitaxel) at
angioplasty sites and thereby reduce neointimal hyperplasia and restenosis follow-
ing endothelial injury caused by the angioplasty [1, 144]. Paclitaxel-coated balloon
(PCB) angioplasty has been successfully used to treat coronary stenosis [145] and
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peripheral vascular disease [146]. In 40 patients with stenotic AVFs and AVGs, PCB
angioplasty resulted in better target lesion and circuit primary patency rates at 6
months compared to high pressure balloon (HPB) angioplasty (70% vs 25% respec-
tively, p < 0.001) [124] . Lai et al. [147] also reported improved AVF patency rate
at 6 months in 10 patients (70% vs 0%, p < 0.01) although this was no longer
statistically significant at 12 months (20% vs 0%, P > 0.05). A subsequent single
center RCT by Kitou et al. [123] randomized 40 patients to receive PCB angioplasty
or HPB angioplasty for dysfunctional AVFs, with a 12-month follow-up (Table 1).
Primary endpoints included device success, anatomic success, clinical success and
target lesion revascularization-free survival with secondary endpoints of dialysis
circuit primary patency and procedure related complications [123]. Use of PCB
angioplasty in dysfunctional AVFs resulted in superior target lesion
revascularization-free survival (PCB 308 days; HPB 161 days; HR 0.478; 95% CI
0.236–0.966, p = 0.03) and dialysis access circuit primary patency (PCB 270 days;
HPB 161 days; HR 0.479; 95% CI 0.237–0.968; p = 0.04) in comparison to HPB
angioplasty, though, additional HPB post dilatation was required in 65% of cases.
Current trial results support the use of PCB angioplasty to prevent re-stenosis in
AVF. However, higher costs compared to conventional angioplasty and the lack of
larger RCTs currently prevent its routine use in clinical practice.
5. Process of care and individualization
Systemic and local therapies to improve arteriovenous access outcomes have
been limited, as outlined above. A multipronged approach including optimization of
process of care may be more powerful to increase the use of AVFs or AVGs, as
opposed to CVCs, than a single therapeutic intervention. An integrated approach to
arteriovenous access care which included nephrologists, vascular surgeons, radiolo-
gists, access coordinators, and scheduled access procedures with tracked outcomes
was demonstrated by Allon et al. [148] to reduce complications associated with
surgical access procedures. These benefits included a 60% decreased rate of AVG
thrombosis, improved graft secondary patency procedures, and an increase in the
AVF creation rate from 33 to 69%. Arora et al. [149] found that patients who were
referred to a nephrologist at least 4 months prior to dialysis initiation were 10 times
more likely to have a successful functioning access at the first dialysis session, with
40% in the early referral group initiating dialysis with permanent vascular access
(80% AVFs, 20% AVGs) vs 4% in the late referral group. This was supported by
Roubicek at el [150] who found that 53% of patients referred early for arteriovenous
access creation had functional AVFs vs 12% who were referred late. Having a
vascular access coordinator can improve the number of AVFs created and decrease
vascular access-related hospitalizations and infections [151]. Other strategies,
including vein preservation policies, patient education regarding vein protection
and access care, preoperative vein mapping and timely access creation have been
found to increase fistula prevalence, decrease primary vascular access failure and
increase cumulative patency [152–154]. The literature suggest that superior arterio-
venous access success is achieved when the AVF is created by a skilled vascular
surgeon, [45–49], with the emphasis being placed on the number of AVFs created
over the total years of training [48, 50]. In the post-operative setting, timely
assessment of arteriovenous access at 4 weeks is recommended to ensure access
function is adequate, and to enable early surgical or endovascular intervention to
prevent or treat primary access failure. Finally, arteriovenous access cannulation by
appropriately trained staff has been shown to prolong AVF survival, while also
minimizing the risk of infection.
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6. Conclusion and future direction
The medical community’s understanding of the pathology and pathogenesis of
vascular access dysfunction has improved dramatically in recent times and enabled
the development of novel targeted treatment approaches. The combination of
interventions focusing on upstream events (i.e. optimization of hemodynamics and
reduction in vascular injury through surgical/endovascular techniques) and down-
stream pathways (antiproliferative and anti-inflammatory therapies) may be a
promising treatment approach to be assessed in future trials. Emphasis of a multi-
pronged approach including optimization of process of care, education, surgical
skills and surveillance combined with targeted therapies may yield the best out-
comes and should be evaluated with innovative trial designs.
Conflict of interest
The authors have no conflict of interest to declare.
Author details
Rebecca Hudson1, David Johnson1,2,3* and Andrea Viecelli1,2
1 Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia
2 Centre for Kidney Disease Research, University of Queensland, Brisbane,
Australia
3 Translational Research Institute, Brisbane, Australia
*Address all correspondence to: david.johnson2@health.qld.gov.au
©2019 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
27
Pathogenesis and Prevention of Vascular Access Failure
DOI: http://dx.doi.org/10.5772/intechopen.83525
References
[1] Riella MC, Roy-Chaudhury P.
Vascular access in haemodialysis:
Strengthening the Achilles' heel. Nature
Reviews. Nephrology. 2013;9(6):
348-357
[2] Broumand B. Diabetes: Changing the
fate of diabetics in the dialysis unit.
Blood Purification. 2007;25(1):39-47
[3] Levin A, Tonelli M, Bonventre J,
Coresh J, Donner JA, Fogo AB, et al.
Global kidney health 2017 and beyond:
A roadmap for closing gaps in care,
research, and policy. Lancet. 2017;
390(10105):1888-1917
[4] Bello AK, Levin A, Tonelli M,
Okpechi IG, Feehally J, Harris D, et al.
Assessment of global kidney health care
status. Journal of the American
Medical Association. 2017;317(18):
1864-1881
[5] Irish AB, Viecelli AK, Hawley CM,
Hooi LS, Pascoe EM, Paul-Brent PA,
et al. Effect of fish oil supplementation
and aspirin use on Arteriovenous fistula
failure in patients requiring
hemodialysis: A randomized clinical
trial. JAMA Internal Medicine. 2017;
177(2):184-193
[6] Liyanage T, Ninomiya T, Jha V, Neal
B, Patrice HM, Okpechi I, et al.
Worldwide access to treatment for end-
stage kidney disease: A systematic
review. Lancet. 2015;385(9981):
1975-1982
[7]Beathard GA, Lok CE, Glickman MH,
Al-Jaishi AA, Bednarski D, Cull DL,
et al. Definitions and end points for
interventional studies for arteriovenous
dialysis access. Clinical Journal of the
American Society of Nephrology. 2018;
13(3):501-512
[8]Hemodialysis Adequacy Work G.
Clinical practice guidelines for
hemodialysis adequacy, update 2006.
American Journal of Kidney Diseases.
2006;48(Supp. 1):S2-S90
[9] Viecelli AK, Pascoe E, Polkinghorne
KR, Hawley C, Paul-Brent PA, Badve
SV, et al. The Omega-3 fatty acids (fish
oils) and aspirin in vascular access
outcomes in renal disease
(FAVOURED) study: The updated final
trial protocol and rationale of post-
initiation trial modifications. BMC
Nephrology. 2015;16:89
[10] Polkinghorne KR, McDonald SP,
Atkins RC, Kerr PG. Vascular access and
all-cause mortality: A propensity score
analysis. Journal of the American
Society of Nephrology. 2004;15(2):
477-486
[11] Allon M, Robbin ML. Increasing
arteriovenous fistulas in hemodialysis
patients: Problems and solutions.
Kidney International. 2002;62(4):
1109-1124
[12] Lok CE, Sontrop JM, Tomlinson G,
Rajan D, Cattral M, Oreopoulos G, et al.
Cumulative patency of contemporary
fistulas versus grafts (2000–2010).
Clinical Journal of the American Society
of Nephrology. 2013;8(5):810-818
[13] Viecelli AK, Mori TA, Roy-
Chaudhury P, Polkinghorne KR, Hawley
CM, Johnson DW, et al. The
pathogenesis of hemodialysis vascular
access failure and systemic therapies for
its prevention: Optimism unfulfilled.
Seminars in Dialysis. 2018;31(3):244-257
[14]Miller PE, Carlton D, Deierhoi MH,
Redden DT, Allon M. Natural history of
arteriovenous grafts in hemodialysis
patients. American Journal of Kidney
Diseases. 2000;36(1):68-74
[15]Dember LM, Beck GJ, Allon M,
Delmez JA, Dixon BS, Greenberg A,
28
Vascular Access Surgery - Tips and Tricks
et al. Effect of clopidogrel on early
failure of arteriovenous fistulas for
hemodialysis: A randomized controlled
trial. Journal of the American Medical
Association. 2008;299(18):2164-2171
[16] Roy-Chaudhury P, Sukhatme VP,
Cheung AK. Hemodialysis vascular
access dysfunction: A cellular and
molecular viewpoint. Journal of the
American Society of Nephrology. 2006;
17(4):1112-1127
[17] Roy-Chaudhury P, Kruskat L.
Future direction for vascular access for
hemodialysis. Seminars in Dialysis.
2014;28(2):107-113
[18]Manns B, Tonelli M, Yilmaz S, Lee
H, Laupland K, Klarenbach S, et al.
Establishment and maintenance of
vascular access in incident hemodialysis
patients: A prospective cost analysis.
Journal of the American Society of
Nephrology. 2005;16(1):201-209
[19] Feldman HI, Kobrin S, Wasserstein
A. Hemodialysis vascular access
morbidity. Journal of the American
Society of Nephrology. 1996;7(4):
523-535
[20] Feldman HI, Held PJ, Hutchinson
JT, Stoiber E, Hartigan MF, Berlin JA.
Hemodialysis vascular access morbidity
in the United States. Kidney
International. 1993;43(5):1091-1096
[21] Tong A, Manns B, Hemmelgarn B,
Wheeler DC, Evangelidis N, Tugwell P,
et al. Establishing core outcome
domains in hemodialysis: Report of the
Standardized Outcomes in Nephrology-
Hemodialysis (SONG-HD) Consensus
Workshop. American Journal of Kidney
Diseases. 2017;69(1):97-107
[22] Lu DY, Chen EY, Wong DJ,
Yamamoto K, Protack CD, Williams
WT, et al. Vein graft adaptation and
fistula maturation in the arterial
environment. The Journal of Surgical
Research. 2014;188(1):162-173
[23] Arer IM, Yabanoglu H. Impact of
surgeon factor on radiocephalic fistula
patency rates. Annals of Medicine and
Surgery (Lond). 2016;5:86-89
[24] Puskar D, Pasini J, Savic I, Bedalov
G, Sonicki Z. Survival of primary
arteriovenous fistula in 463 patients on
chronic hemodialysis. Croatian Medical
Journal. 2002;43(3):306-311
[25]Miller CD, Robbin ML, Allon M.
Gender differences in outcomes of
arteriovenous fistulas in hemodialysis
patients. Kidney International. 2003;
63(1):346-352
[26] Jennings WC, Landis L, Taubman
KE, Parker DE. Creating functional
autogenous vascular access in older
patients. Journal of Vascular Surgery.
2011;53(3):713-719; discussion 9
[27]Diehm N, van den Berg JC,
Schnyder V, Buhler J, Willenberg T,
Widmer M, et al. Determinants of
haemodialysis access survival. VASA
Journal. 2010;39(2):133-139
[28]Marcus RJ, Marcus DA,
Sureshkumar KK, Hussain SM, McGill
RL. Gender differences in vascular
access in hemodialysis patients in the
United States: Developing strategies for
improving access outcome. Gender
Medicine. 2007;4(3):193-204
[29] Caplin N, Sedlacek M, Teodorescu
V, Falk A, Uribarri J. Venous access:
Women are equal. American Journal of
Kidney Diseases. 2003;41(2):429-432
[30] Chitalia N, Ross L, Krishnamoorthy
M, Kapustin A, Shanahan CM, Kaski JC,
et al. Neointimal hyperplasia and
calcification in medium sized arteries in
adult patients with chronic kidney
disease. Seminars in Dialysis. 2015;
28(3):E35-E40
29
Pathogenesis and Prevention of Vascular Access Failure
DOI: http://dx.doi.org/10.5772/intechopen.83525
[31]Woods JD, Turenne MN,
Strawderman RL, Young EW, Hirth RA,
Port FK, et al. Vascular access survival
among incident hemodialysis patients in
the United States. American Journal of
Kidney Diseases. 1997;30(1):50-57
[32] Zarins CK, Zatina MA, Giddens DP,
Ku DN, Glagov S. Shear stress
regulation of artery lumen diameter in
experimental atherogenesis. Journal of
Vascular Surgery. 1987;5(3):413-420
[33]Dixon BS. Why don't fistulas
mature? Kidney International. 2006;
70(8):1413-1422
[34] Righetti M, Ferrario G, Serbelloni P,
Milani S, Tommasi A. Some old drugs
improve late primary patency rate of
native arteriovenous fistulas in
hemodialysis patients. Annals of
Vascular Surgery. 2009;23(4):491-497
[35] Kim YO, Song HC, Yoon SA, Yang
CW, Kim NI, Choi YJ, et al. Preexisting
intimal hyperplasia of radial artery is
associated with early failure of
radiocephalic arteriovenous fistula in
hemodialysis patients. American Journal
of Kidney Diseases. 2003;41(2):422-428
[36] Beks PJ, Mackaay AJ, de Neeling JN,
de Vries H, Bouter LM, Heine RJ.
Peripheral arterial disease in relation to
glycaemic level in an elderly Caucasian
population: The Hoorn study.
Diabetologia. 1995;38(1):86-96
[37] Konner K. Primary vascular access
in diabetic patients: An audit.
Nephrology, Dialysis, Transplantation.
2000;15(9):1317-1325
[38] Ravani P, Marcelli D, Malberti F.
Vascular access surgery managed by
renal physicians: The choice of native
arteriovenous fistulas for hemodialysis.
American Journal of Kidney Diseases.
2002;40(6):1264-1276
[39] Peterson WJ, Barker J, Allon M.
Disparities in fistula maturation persist
despite preoperative vascular mapping.
Clinical Journal of the American Society
of Nephrology. 2008;3(2):437-441
[40]Miller PE, Tolwani A, Luscy CP,
Deierhoi MH, Bailey R, Redden DT,
et al. Predictors of adequacy of
arteriovenous fistulas in hemodialysis
patients. Kidney International. 1999;
56(1):275-280
[41] Lok CE, Allon M, Moist L, Oliver
MJ, Shah H, Zimmerman D. Risk
equation determining unsuccessful
cannulation events and failure to
maturation in arteriovenous fistulas
(REDUCE FTM I). Journal of the
American Society of Nephrology. 2006;
17(11):3204-3212
[42]Obialo CI, Tagoe AT, Martin PC,
Asche-Crowe PE. Adequacy and
survival of autogenous arteriovenous
fistula in African American
hemodialysis patients. ASAIO Journal.
2003;49(4):435-439
[43]Wilmink T, Wijewardane A, Lee K,
Murley A, Hollingworth L, Powers S,
et al. Effect of ethnicity and
socioeconomic status on vascular access
provision and performance in an urban
NHS hospital. Clinical Kidney Journal.
2017;10(1):62-67
[44]Woo K, Gascue L, Goldman DP,
Romley JA. Variations in outcomes of
hemodialysis vascular access by race/
ethnicity in the elderly. Journal of
Vascular Surgery. 2017;65(3):783-792 e4
[45]O'Hare AM, Dudley RA, Hynes DM,
McCulloch CE, Navarro D, Colin P,
et al. Impact of surgeon and surgical
center characteristics on choice of
permanent vascular access. Kidney
International. 2003;64(2):681-689
[46]Huijbregts HJ, Bots ML, Moll FL,
Blankestijn PJ, CIMINO members.
Hospital specific aspects predominantly
determine primary failure of
hemodialysis arteriovenous fistulas.
30
Vascular Access Surgery - Tips and Tricks
Journal of Vascular Surgery. 2007;45(5):
962-967
[47]He C, Charoenkul V, Kahn T,
Langhoff E, Uribarri J, Sedlacek M.
Impact of the surgeon on the prevalence
of arteriovenous fistulas. ASAIO
Journal. 2002;48(1):39-40
[48] Goodkin DA, Pisoni RL, Locatelli F,
Port FK, Saran R. Hemodialysis vascular
access training and practices are key to
improved access outcomes. American
Journal of Kidney Diseases. 2010;56(6):
1032-1042
[49] Choi KL, Salman L, Krishnamurthy
G, Mercado C, Merrill D, Thomas I,
et al. Impact of surgeon selection on
access placement and survival following
preoperative mapping in the "Fistula
First" era. Seminars in Dialysis. 2008;
21(4):341-345
[50] Saran R, Elder SJ, Goodkin DA,
Akiba T, Ethier J, Rayner HC, et al.
Enhanced training in vascular access
creation predicts arteriovenous fistula
placement and patency in hemodialysis
patients: Results from the Dialysis
Outcomes and Practice Patterns
Study. Annals of Surgery. 2008;247(5):
885-891
[51] Kats M, Hawxby AM, Barker J,
Allon M. Impact of obesity on
arteriovenous fistula outcomes in
dialysis patients. Kidney International.
2007;71(1):39-43
[52] Plumb TJ, Adelson AB, Groggel GC,
Johanning JM, Lynch TG, Lund B.
Obesity and hemodialysis vascular
access failure. American Journal of
Kidney Diseases. 2007;50(3):450-454
[53] Conte MS, Nugent HM, Gaccione P,
Roy-Chaudhury P, Lawson JH.
Influence of diabetes and perivascular
allogeneic endothelial cell implants on
arteriovenous fistula remodeling.
Journal of Vascular Surgery. 2011;54(5):
1383-1389
[54] Parisotto MT, Schoder VU, Miriunis
C, Grassmann AH, Scatizzi LP,
Kaufmann P, et al. Cannulation
technique influences arteriovenous
fistula and graft survival.
Kidney International. 2014;86(4):
790-797
[55] Tordoir J, Canaud B, Haage P,
Konner K, Basci A, Fouque D, et al.
EBPG on vascular access. Nephrology
Dialysis Transplantation. 2007;22
(Suppl_2):ii88-ii117
[56] Jindal K, Chan CT, Deziel C, Hirsch
D, Soroka SD, Tonelli M, et al. Vascular
access. Journal of the American Society
of Nephrology. 2006;17(3 supp. 1):
S16-S23
[57] Jindal K, Chan CT, Deziel C, Hirsch
D, Soroka SD, Tonelli M, et al.
Hemodialysis clinical practice guidelines
for the Canadian Society of Nephrology.
Journal of the American Society of
Nephrology. 2006;17(3 supp. 1):S1
[58] Polkinghorne KR, Chin GK,
MacGinley RJ, Owen AR, Russell C,
Talaulikar GS, et al. KHA-CARI
guideline: Vascular access—Central
venous catheters, arteriovenous fistulae
and arteriovenous grafts. Nephrology.
2013;18(11):701-705
[59]McCann M, Einarsdottir H, Van
Waeleghem JP, Murphy F, Sedgwick J.
Vascular access management II: AVF/
AVG cannulation techniques and
complications. Journal of Renal Care.
2009;35(2):90-98
[60] Feinfeld DA, Batista R, Mir R,
Babich D. Changes in venous histology
in chronic hemodialysis patients.
American Journal of Kidney Diseases.
1999;34(4):702-705
[61] Falk A, Teodorescu V, Lou WY,
Uribarri J, Vassalotti JA. Treatment of
"swing point stenoses" in hemodialysis
arteriovenous fistulae. Clinical
Nephrology. 2003;60(1):35-41
31
Pathogenesis and Prevention of Vascular Access Failure
DOI: http://dx.doi.org/10.5772/intechopen.83525
[62] Shenoy S, Woodward RS. Economic
impact of the beneficial effect of
changing vascular anastomotic
technique in hemodialysis access.
Vascular and Endovascular Surgery.
2005;39(5):437-443
[63] Rothuizen TC, Wong C, Quax PH,
van Zonneveld AJ, Rabelink TJ,
Rotmans JI. Arteriovenous access
failure: More than just intimal
hyperplasia? Nephrology, Dialysis,
Transplantation. 2013;28(5):1085-1092
[64] Cooke JP, Rossitch E Jr, Andon NA,
Loscalzo J, Dzau VJ. Flow activates an
endothelial potassium channel to release
an endogenous nitrovasodilator. The
Journal of Clinical Investigation. 1991;
88(5):1663-1671
[65] Ene-Iordache B, Mosconi L, Antiga
L, Bruno S, Anghileri A, Remuzzi G,
et al. Radial artery remodeling in
response to shear stress increase within
arteriovenous fistula for hemodialysis
access. Endothelium. 2003;10(2):95-102
[66] Langer S, Heiss C, Paulus N, Bektas
N, Mommertz G, Rowinska Z, et al.
Functional and structural response of
arterialized femoral veins in a rodent
AV fistula model. Nephrology, Dialysis,
Transplantation. 2009;24(7):2201-2206
[67]Harter HR, Burch JW, Majerus PW,
Stanford N, Delmez JA, Anderson CB,
et al. Prevention of thrombosis in
patients on hemodialysis by low-dose
aspirin. The New England Journal of
Medicine. 1979;301(11):577-579
[68] Andrassy K, Malluche H, Bornefeld
H, Comberg M, Ritz E, Jesdinsky H,
et al. Prevention of p.o. clotting of av.
cimino fistulae with acetylsalicyl acid.
Results of a prospective double blind
study. Klinische Wochenschrift. 1974;
52(7):348-349
[69] Sreedhara R, Himmelfarb J, Lazarus
JM, Hakim RM. Anti-platelet therapy in
graft thrombosis: Results of a
prospective, randomized, double-blind
study. Kidney International. 1994;45(5):
1477-1483
[70]Harker LA, Kadatz RA. Mechanism
of action of dipyridamole. Thrombosis
Research. Supplement. 1983;4:39-46
[71]Himmelfarb J, Couper L.
Dipyridamole inhibits PDGF- and
bFGF-induced vascular smooth muscle
cell proliferation. Kidney International.
1997;52(6):1671-1677
[72]Dixon BS, Beck GJ, Vazquez MA,
Greenberg A, Delmez JA, Allon M, et al.
Effect of dipyridamole plus aspirin on
hemodialysis graft patency. The New
England Journal of Medicine. 2009;
360(21):2191-2201
[73]Ghorbani A, Aalamshah M,
Shahbazian H, Ehsanpour A, Aref A.
Randomized controlled trial of
clopidogrel to prevent primary
arteriovenous fistula failure in
hemodialysis patients. Indian Journal of
Nephrology. 2009;19(2):57-61
[74] Kaufman JS, O'Connor TZ, Zhang
JH, Cronin RE, Fiore LD, Ganz MB,
et al. Randomized controlled trial of
clopidogrel plus aspirin to prevent
hemodialysis access graft thrombosis.
Journal of the American Society of
Nephrology. 2003;14(9):2313-2321
[75]Grontoft KC, Mulec H, Gutierrez A,
Olander R. Thromboprophylactic effect
of ticlopidine in arteriovenous fistulas
for haemodialysis. Scandinavian Journal
of Urology and Nephrology. 1985;19(1):
55-57
[76] Fiskerstrand CE, Thompson IW,
Burnet ME, Williams P, Anderton JL.
Double-blind randomized trial of the
effect of ticlopidine in arteriovenous
fistulas for hemodialysis. Artificial
Organs. 1985;9(1):61-63
[77]Grontoft KC, Larsson R, Mulec H,
Weiss LG, Dickinson JP. Effects of
32
Vascular Access Surgery - Tips and Tricks
ticlopidine in AV-fistula surgery in
uremia. Fistula Study Group.
Scandinavian Journal of Urology and
Nephrology. 1998;32(4):276-283
[78] Tanner NC, Da Silva A. Medical
adjuvant treatment to increase patency
of arteriovenous fistulae and grafts.
Cochrane Database of Systematic
Reviews. 2015;7:CD002786
[79] Palmer SC, Di Micco L, Razavian M,
Craig JC, Ravani P, Perkovic V, et al.
Antiplatelet therapy to prevent
hemodialysis vascular access failure:
Systematic review and meta-analysis.
American Journal of Kidney Diseases.
2013;61(1):112-122
[80] Kaufman JS. Antithrombotic agents
and the prevention of access
thrombosis. Seminars in Dialysis. 2000;
13(1):40-46
[81] Viecelli AK, Irish AB, Polkinghorne
KR, Hawley CM, Johnson DW, Mori
TA, et al. Omega-3 polyunsaturated
fatty acid supplementation to prevent
arteriovenous fistula and graft failure: A
systematic review and meta-analysis of
randomized controlled trials. American
Journal of Kidney Diseases. 2018;72(1):
50-61
[82] Fox PL, DiCorleto PE. Fish oils
inhibit endothelial cell production of
platelet-derived growth factor-like
protein. Science. 1988;241(4864):
453-456
[83] Rylance PB, Gordge MP, Saynor R,
Parsons V, Weston MJ. Fish oil modifies
lipids and reduces platelet aggregability
in haemodialysis patients. Nephron.
1986;43(3):196-202
[84] Calder PC. Omega-3
polyunsaturated fatty acids and
inflammatory processes: Nutrition or
pharmacology? British Journal of
Clinical Pharmacology. 2013;75(3):
645-662
[85]Wang Q, Liang X, Wang L, Lu X,
Huang J, Cao J, et al. Effect of omega-3
fatty acids supplementation on
endothelial function: A meta-analysis of
randomized controlled trials.
Atherosclerosis. 2012;221(2):536-543
[86]Hung AM, Booker C, Ellis CD, Siew
ED, Graves AJ, Shintani A, et al. Omega-
3 fatty acids inhibit the up-regulation of
endothelial chemokines in maintenance
hemodialysis patients. Nephrology,
Dialysis, Transplantation. 2015;30(2):
266-274
[87] Friedman A, Moe S. Review of the
effects of omega-3 supplementation in
dialysis patients. Clinical Journal of the
American Society of Nephrology. 2006;
1(2):182-192
[88] Schmitz PG, McCloud LK, Reikes
ST, Leonard CL, Gellens ME.
Prophylaxis of hemodialysis graft
thrombosis with fish oil: Double-blind,
randomized, prospective trial. Journal of
the American Society of Nephrology.
2002;13(1):184-190
[89] Lok CE, Moist L, Hemmelgarn BR,
Tonelli M, Vazquez MA, Dorval M, et al.
Effect of fish oil supplementation on
graft patency and cardiovascular events
among patients with new synthetic
arteriovenous hemodialysis grafts: A
randomized controlled trial. Journal of
the American Medical Association.
2012;307(17):1809-1816
[90] Bowden RG, Wilson RL, Gentile M,
Ounpraseuth S, Moore P, Leutholtz BC.
Effects of omega-3 fatty acid
supplementation on vascular access
thrombosis in polytetrafluorethylene
grafts. Journal of Renal Nutrition. 2007;
17(2):126-131
[91] Birch N, Fillaus J, Florescu MC. The
effect of statin therapy on the formation
of arteriovenous fistula stenoses and the
rate of reoccurrence of previously
treated stenoses. Hemodialysis
International. 2013;17(4):586-593
33
Pathogenesis and Prevention of Vascular Access Failure
DOI: http://dx.doi.org/10.5772/intechopen.83525
[92] Janardhanan R, Yang B, Vohra P,
Roy B, Withers S, Bhattacharya S, et al.
Simvastatin reduces venous stenosis
formation in a murine hemodialysis
vascular access model. Kidney
International. 2013;84(2):338-352
[93] Tsiara S, Elisaf M, Mikhailidis DP.
Early vascular benefits of statin therapy.
Current Medical Research and Opinion.
2003;19(6):540-556
[94]Herrington W, Emberson J, Staplin
N, Blackwell L, Fellstrom B, Walker R,
et al. The effect of lowering LDL
cholesterol on vascular access patency:
Post hoc analysis of the study of heart
and renal protection. Clinical Journal of
the American Society of Nephrology.
2014;9(5):914-919
[95]Wanner C, Krane V, Marz W,
Olschewski M, Asmus HG, Kramer W,
et al. Randomized controlled trial on the
efficacy and safety of atorvastatin in
patients with typ. 2 diabetes on
hemodialysis (4D study): Demographic
and baseline characteristics. Kidney &
Blood Pressure Research. 2004;27(4):
259-266
[96] Saran R, Dykstra DM, Wolfe RA,
Gillespie B, Held PJ, Young EW.
Association between vascular access
failure and the use of specific drugs: The
Dialysis outcomes and practice patterns
study (DOPPS). American Journal of
Kidney Diseases. 2002;40(6):1255-1263
[97] Pisoni R, Barker-Finkel J, Allon M.
Statin therapy is not associated with
improved vascular access outcomes.
Clinical Journal of the American Society
of Nephrology. 2010;5(8):1447-1450
[98] Sajgure A, Choudhury A, Ahmed Z,
Choudhury D. Angiotensin converting
enzyme inhibitors maintain
polytetrafluoroethylene graft patency.
Nephrology, Dialysis, Transplantation.
2007;22(5):1390-1398
[99] Jackson RS, Sidawy AN, Amdur RL,
Khetarpal A, Macsata RA. Angiotensin
receptor blockers and antiplatelet agents
are associated with improved primary
patency after arteriovenous
hemodialysis access placement. Journal
of Vascular Surgery. 2011;54(6):
1706-1712
[100] Yamada T, Kondo T, Numaguchi
Y, Tsuzuki M, Matsubara T, Manabe I,
et al. Angiotensin II receptor blocker
inhibits neointimal hyperplasia through
regulation of smooth muscle-like
progenitor cells. Arteriosclerosis,
Thrombosis, and Vascular Biology.
2007;27(11):2363-2369
[101]O'Donohoe MK, Schwartz LB,
Radic ZS, Mikat EM, McCann RL,
Hagen PO. Chronic ACE inhibition
reduces intimal hyperplasia in
experimental vein grafts. Annals of
Surgery. 1991;214(6):727-732
[102] Yagi S, Morita T, Katayama S.
Combined treatment with an AT1
receptor blocker and angiotensin
converting enzyme inhibitor has an
additive effect on inhibiting neointima
formation via improvement of nitric
oxide production and suppression of
oxidative stress. Hypertension Research.
2004;27(2):129-135
[103] Baan J Jr, Chang PC, Vermeij P,
Pfaffendorf M, van Zwieten PA.
Venoconstriction by angiotensin II in
the human forearm is inhibited by
losartan but not by nicardipine. Journal
of Cardiovascular Pharmacology. 1998;
31(1):50-55
[104] Kalinowski L, Matys T, Chabielska
E, Buczko W, Malinski T. Angiotensin II
AT1 receptor antagonists inhibit platelet
adhesion and aggregation by nitric oxide
release. Hypertension. 2002;40(4):
521-527
[105] Katoh M, Egashira K, Mitsui T,
Chishima S, Takeshita A, Narita H.
Angiotensin-converting enzyme
inhibitor prevents plasminogen
activator inhibitor-1 expression in a rat
model with cardiovascular remodeling
34
Vascular Access Surgery - Tips and Tricks
induced by chronic inhibition of nitric
oxide synthesis. Journal of Molecular
and Cellular Cardiology. 2000;32(1):
73-83
[106]Moon JY, Jeong KH, Paik SS, Han
JJ, Lee SH, Lee TW, et al. Arteriovenous
fistula patency associated with
angiotensin-converting enzyme I/D
polymorphism and ACE inhibition or
AT1 receptor blockade. Nephron.
Clinical Practice. 2009;111(2):
c110-c116
[107]Diskin CJ, Stokes TJ, Thomas SG,
Ravis W, Lock S, Thomas J, et al. An
analysis of the effect of routine
medications on hemodialysis vascular
access survival. Nephron. 1998;78(3):
365-368
[108] Chen FA, Chien CC, Chen YW,
Wu YT, Lin CC. Angiotensin
converting-enzyme inhibitors,
angiotensin receptor blockers, and
calcium channel blockers are associated
with prolonged vascular access patency
in uremic patients undergoing
hemodialysis. PLoS One. 2016;11(11):
e0166362
[109] Taber TE, Maikranz PS, Haag BW,
Gaylord GM, Dilley RS, Ehrman KO,
et al. Maintenance of adequate
hemodialysis access. Prevention of
neointimal hyperplasia. ASAIO Journal.
1995;41(4):842-846
[110]Huang P, Hawthorne WJ, Peng A,
Angeli GL, Medbury HJ, Fletcher JP.
Calcium channel antagonist verapamil
inhibits neointimal formation and
enhances apoptosis in a vascular graft
model. American Journal of Surgery.
2001;181(6):492-498
[111] Bashar K, Zafar A, Elsheikh S,
Healy DA, Clarke-Moloney M, Casserly
L, et al. Predictive parameters of
arteriovenous fistula functional
maturation in a population of patients
with end-stage renal disease. PLoS One.
2015;10(3):e0119958
[112]Doi S, Masaki T, Shigemoto K,
Harada S, Yorioka N. Calcium channel
antagonists reduce restenosis after
percutaneous transluminal angioplasty
of an arteriovenous fistula in
hemodialysis patients. Therapeutic
Apheresis and Dialysis. 2008;12(3):
232-236
[113]Manson RJ, Ebner A, Gallo S,
Chemla E, Mantell M, Deaton D, et al.
Arteriovenous fistula creation using the
optiflow vascular anastomosis device: A
first in man pilot study. Seminars in
Dialysis. 2013;26(1):97-99
[114] Lok CE, Rajan DK, Clement J, Kiaii
M, Sidhu R, Thomson K, et al.
Endovascular proximal forearm
arteriovenous fistula for hemodialysis
access: Results of the prospective,
multicenter Novel Endovascular Access
Trial (NEAT). American Journal of
Kidney Diseases. 2017;70(4):486-497
[115] Lin CC, Yang WC, Chen MC, Liu
WS, Yang CY, Lee PC. Effect of far
infrared therapy on arteriovenous
fistula maturation: An open-label
randomized controlled trial. American
Journal of Kidney Diseases. 2013;62(2):
304-311
[116] Lin CC, Chang CF, Lai MY, Chen
TW, Lee PC, Yang WC. Far-infrared
therapy: A novel treatment to improve
access blood flow and unassisted
patency of arteriovenous fistula in
hemodialysis patients. Journal of the
American Society of Nephrology. 2007;
18(3):985-992
[117]Hye RJ, Peden EK, O'Connor TP,
Browne BJ, Dixon BS, Schanzer AS,
et al. Human type I pancreatic elastase
treatment of arteriovenous fistulas in
patients with chronic kidney disease.
Journal of Vascular Surgery. 2014;60(2):
454-461 e1
[118]Dwivedi AJ, Roy-Chaudhury P,
Peden EK, Browne BJ, Ladenheim ED,
Scavo VA, et al. Application of human
type I pancreatic elastase (PRT-201) to
35
Pathogenesis and Prevention of Vascular Access Failure
DOI: http://dx.doi.org/10.5772/intechopen.83525
the venous anastomosis of arteriovenous
grafts in patients with chronic kidney
disease. The Journal of Vascular Access.
2014;15(5):376-384
[119]Nugent HM, Sjin RT, White D,
Milton LG, Manson RJ, Lawson JH, et al.
Adventitial endothelial implants reduce
matrix metalloproteinase-2 expression
and increase luminal diameter in
porcine arteriovenous grafts. Journal of
Vascular Surgery. 2007;46(3):548-556
[120]Nugent HM, Groothuis A, Seifert
P, Guerraro JL, Nedelman M,
Mohanakumar T, et al. Perivascular
endothelial implants inhibit intimal
hyperplasia in a model of arteriovenous
fistulae: A safety and efficacy study in
the pig. Journal of Vascular Research.
2002;39(6):524-533
[121] Conte MS, Nugent HM, Gaccione P,
Guleria I, Roy-Chaudhury P, Lawson JH.
Multicenter phase I/II trial of the safety
of allogeneic endothelial cell implants
after the creation of arteriovenous access
for hemodialysis use: The V-HEALTH
study. Journal of Vascular Surgery. 2009;
50(6):1359-1368 e1
[122] Paulson WD, Kipshidze N, Kipiani
K, Beridze N, DeVita MV, Shenoy S,
et al. Safety and efficacy of local
periadventitial delivery of sirolimus for
improving hemodialysis graft patency:
First human experience with a
sirolimus-eluting collagen membrane
(Coll-R). Nephrology, Dialysis,
Transplantation. 2012;27(3):1219-1224
[123] Kitrou PM, Spiliopoulos S,
Katsanos K, Papachristou E, Siablis D,
Karnabatidis D. Paclitaxel-coated versus
plain balloon angioplasty for
dysfunctional arteriovenous fistulae:
One-year results of a prospective
randomized controlled trial. Journal of
Vascular and Interventional Radiology.
2015;26(3):348-354
[124] Katsanos K, Karnabatidis D, Kitrou
P, Spiliopoulos S, Christeas N, Siablis D.
Paclitaxel-coated balloon angioplasty vs.
plain balloon dilation for the treatment
of failing dialysis access: 6-month
interim results from a prospective
randomized controlled trial. Journal of
Endovascular Therapy. 2012;19(2):
263-272
[125] Remuzzi A, Ene-Iordache B. Novel
paradigms for dialysis vascular access:
Upstream hemodynamics and vascular
remodeling in dialysis access stenosis.
Clinical Journal of the American
Society of Nephrology. 2013;8(12):
2186-2193
[126] Bharat A, Jaenicke M, Shenoy S. A
novel technique of vascular anastomosis
to prevent juxta-anastomotic stenosis
following arteriovenous fistula creation.
Journal of Vascular Surgery. 2012;55(1):
274-280
[127] Chemla E, Tavakoli A, Nikam M,
Mitra S, Malete T, Evans J, et al.
Arteriovenous fistula creation using the
Optiflow vascular anastomotic
connector: The OPEN (Optiflow
PatEncy and MaturatioN) study. The
Journal of Vascular Access. 2014;15(1):
38-44
[128] Lee T, Roy-Chaudhury P.
Advances and new frontiers in the
pathophysiology of venous neointimal
hyperplasia and dialysis access stenosis.
Advances in Chronic Kidney Disease.
2009;16(5):329-338
[129]Hartel M, Hoffmann G, Wente
MN, Martignoni ME, Buchler MW,
Friess H. Randomized clinical trial of the
influence of local water-filtered infrared
A irradiation on wound healing after
abdominal surgery. The British Journal
of Surgery. 2006;93(8):952-960
[130] Imamura M, Biro S, Kihara T,
Yoshifuku S, Takasaki K, Otsuji Y, et al.
Repeated thermal therapy improves
impaired vascular endothelial function
in patients with coronary risk
factors. Journal of the American
College of Cardiology. 2001;38(4):
1083-1088
36
Vascular Access Surgery - Tips and Tricks
[131]Wan Q, Yang S, Li L, Chu F.
Effects of far infrared therapy on
arteriovenous fistulas in hemodialysis
patients: A meta-analysis. Renal Failure.
2017;39(1):613-622
[132]Dobrin PB, Canfield TR. Elastase,
collagenase, and the biaxial elastic
properties of dog carotid artery. The
American Journal of Physiology. 1984;
247(1 Pt 2):H124-H131
[133] Tani T, Kawashima I, Furukawa H,
Ohmine T, Takiguchi Y.
Characterization of a silent gene for
human pancreatic elastase I: Structure of
the 50-flanking region. Journal of
Biochemistry. 1987;101(3):591-599
[134] Talas U, Dunlop J, Khalaf S, Leigh
IM, Kelsell DP. Human elastase 1:
Evidence for expression in the skin and
the identification of a frequent
frameshift polymorphism. The Journal
of Investigative Dermatology. 2000;
114(1):165-170
[135] Peden EK, Leeser DB, Dixon BS, El-
Khatib MT, Roy-Chaudhury P, Lawson
JH, et al. A multi-center, dose-escalation
study of human type I pancreatic
elastase (PRT-201) administered after
arteriovenous fistula creation. The
Journal of Vascular Access. 2013;14(2):
143-151
[136]Qamar AA, Burke SK, Lafleur JD,
Ding BC, Bland KS, Wong MD, et al.
The ability of serum from alpha
1-antitrypsin-deficient patients to
inhibit PRT-201, a recombinant human
type I pancreatic elastase. Biotechnology
and Applied Biochemistry. 2012;59(1):
22-28
[137]Hance K, Franano F, Henry C.
Prot-101 dilates AV fistula (AVF)
outflow veins and reduces intimal
hyperplasia in a rabbit model. Journal of
the American Society of Nephrology.
2005;16:11A
[138] Franano FN, Hance K, Bland K,
Burke S. PRT-201 dilates outflow veins
and improves maturation rates in a
rabbit model of AVF. In: Nephrology
Dialysis Transplantation. Oxford,
England: Oxford Univ Press; 2007
[139] Charron T, Nili N, Strauss BH. The
cell cycle: A critical therapeutic target to
prevent vascular proliferative disease.
The Canadian Journal of Cardiology.
2006;22(Suppl B):41B-55B
[140] Zhu W, Masaki T, Cheung AK,
Kern SE. In-vitro release of Rapamycin
from a thermosensitive polymer for the
inhibition of vascular smooth muscle
cell proliferation. Journal of
Bioequivalence and Bioavailability.
2009;1:3-12
[141]Morice MC, Serruys PW, Barragan
P, Bode C, Van Es GA, Stoll HP, et al.
Long-term clinical outcomes with
sirolimus-eluting coronary stents: Five-
year results of the RAVEL trial. Journal
of the American College of Cardiology.
2007;50(14):1299-1304
[142] Yachi S, Tanabe K, Tanimoto S,
Aoki J, Nakazawa G, Yamamoto H, et al.
Clinical and angiographic outcomes
following percutaneous coronary
intervention with sirolimus-eluting
stents versus bare-metal stents in
hemodialysis patients. American Journal
of Kidney Diseases. 2009;54(2):299-306
[143]Weisz G, Leon MB, Holmes DR Jr,
Kereiakes DJ, Popma JJ, Teirstein PS,
et al. Five-year follow-up after
sirolimus-eluting stent implantation
results of the SIRIUS (Sirolimus-Eluting
Stent in De-Novo Native Coronary
Lesions) trial. Journal of the American
College of Cardiology. 2009;53(17):
1488-1497
[144] Roy-Chaudhury P, Kruska L.
Future directions for vascular access for
hemodialysis. Seminars in Dialysis.
2015;28(2):107-113
[145] Scheller B, Hehrlein C, Bocksch W,
Rutsch W, Haghi D, Dietz U, et al.
Treatment of coronary in-stent
37
Pathogenesis and Prevention of Vascular Access Failure
DOI: http://dx.doi.org/10.5772/intechopen.83525
restenosis with a paclitaxel-coated
balloon catheter. The New England
Journal of Medicine. 2006;355(20):
2113-2124
[146] Tepe G, Zeller T, Albrecht T,
Heller S, Schwarzwalder U, Beregi JP,
et al. Local delivery of paclitaxel to
inhibit restenosis during angioplasty of
the leg. The New England Journal of
Medicine. 2008;358(7):689-699
[147] Lai CC, Fang HC, Tseng CJ, Liu CP,
Mar GY. Percutaneous angioplasty using
a paclitaxel-coated balloon improves
target lesion restenosis on inflow lesions
of autogenous radiocephalic fistulas: A
pilot study. Journal of Vascular and
Interventional Radiology. 2014;25(4):
535-541
[148] Allon M, Bailey R, Ballard R,
Deierhoi MH, Hamrick K, Oser R, et al.
A multidisciplinary approach to
hemodialysis access: Prospective
evaluation. Kidney International. 1998;
53(2):473-479
[149] Arora P, Obrador GT, Ruthazer R,
KAUSZ AT, Meyer KB, Jenuleson CS,
et al. Prevalence, predictors, and
consequences of late nephrology referral
at a tertiary care center. Journal of the
American Society of Nephrology. 1999;
10(6):1281-1286
[150] Roubicek C, Brunet P, Huiart L,
Thirion X, Leonetti F, Dussol B, et al.
Timing of nephrology referral: Influence
on mortality and morbidity. American
Journal of Kidney Diseases. 2000;36(1):
35-41
[151]Dwyer A, Shelton P, Brier M,
Aronoff G. A vascular access
coordinator improves the prevalent
fistula rate. Seminars in Dialysis. 2012;
25(2):239-243
[152] Silva MB Jr, Hobson II RW, Pappas
PJ, Jamil Z, Araki CT, Goldberg MC,
et al. A strategy for increasing use of
autogenous hemodialysis access
procedures: Impact of preoperative
noninvasive evaluation. Journal of
Vascular Surgery. 1998;27(2):302-308
[153] Robbin ML, Gallichio MH,
Deierhoi MH, Young CJ, Weber TM,
Allon M. US vascular mapping before
hemodialysis access placement.
Radiology. 2000;217(1):83-88
[154] Allon M, Lockhart ME, Lilly RZ,
Gallichio MH, Young CJ, Barker J, et al.
Effect of preoperative sonographic
mapping on vascular access outcomes in
hemodialysis patients. Kidney
International. 2001;60(5):2013-2020
38
Vascular Access Surgery - Tips and Tricks
